Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellow, Cardiology, Duke University School of Medicine 1986 - 1988
  • Resident, Internal Medicine, Barnes-Jewish Hospital 1983 - 1985
  • Intern, Internal Medicine, Barnes-Jewish Hospital 1982 - 1983
  • M.D., Johns Hopkins University 1982
• 

  Medical Licensure

  • 0101058287. Virginia. 1994
  • 32586. North Carolina. 1986
• 

  Previous Appointments & Affiliations

  • Associate Professor in Community and Family Medicine, Family Medicine and Community Health, Clinical Science Departments 2004 - 2008
  • Associate Professor of Medicine with Tenure, Medicine, Cardiology, Medicine 1999 - 2007
  • Associate Professor of Medicine, Medicine, Cardiology, Medicine 1997 - 1999
  • Assistant Professor of Medicine, Medicine, Cardiology, Medicine 1990 - 1997
  • Associate in the Department of Medicine, Medicine, Clinical Science Departments 1988 - 1989
• Recognition
• 

  Awards & Honors

  • Distinguished Service. American College of Cardiology. March 2018
  • Master Clinician / Teacher. Duke University Health System. May 2015
  • Strength, Hope and Caring. Duke University Health System. November 2004
• Expertise
• 

  Subject Headings

  • Angioplasty
  • Coronary Angiography
  • Coronary Artery Disease
  • Informatics
  • Stents
• 

  Global Scholarship

  • Expertise

    • United States of America 
• Research
• 

  Selected Grants

  • Core variable Assessment Towards a NatIonal evaluation Program (CATNIP) - Subcontract with Weill Cornell awarded by Weill Cornell Medicine 2020 - 2021
  • Building UDI Into Longitudinal Data for Medical Device Evaluation (BUILD) awarded by Mercy Health 2018 - 2021
  • PCI QA Review awarded by The Foundation of FirstHealth 2019 - 2020
  • Optimizing the Electronic Health Record for Cardiac Care awarded by University of Nebraska 2014 - 2019
  • Improvement of interoperability of healthcare data awarded by Pew Charitable Trusts 2018
  • BUILD awarded by Mercy Health 2016 - 2017
  • Advancing Medical Device Postmarket Surveillance Infrastructure and Epidemiologic Methodologies through Multi-stakeholder Partnership (U01) awarded by Food and Drug Administration 2013 - 2017
  • Population-based Surveillance And Outcomes of Venous Thromboembolism awarded by Centers for Disease Control and Prevention 2012 - 2015
  • Standardized Collection and Submission of Cardiovascular Endpoint Data awarded by Food and Drug Administration 2012 - 2013
  • Data Concepts and Terminology Standards in Cardiovascular Imaging (R24) awarded by Food and Drug Administration 2012 - 2013
  • Synthesis and Harmonization of High Impact Data Elements awarded by Food and Drug Administration 2011 - 2013
  • CTSA UL awarded by National Institutes of Health 2006 - 2012
• 

  External Relationships

  • Alliance for the Implmentation of Clinical Practice Guidelines
  • American Board of Internal Medicine
  • American College of Cardiology Foundation
  • American Medical Foundation
  • HL7
  • Haug Partners
  • Logica Health
  • Pattern Health
  • Regenstrief Foundation
• Publications & Artistic Works
• 

  Selected Publications

  • Books

    • Watson, Timothy J., Paul J. L. Ong, and James E. Tcheng. Primary Angioplasty A Practical Guide. Springer, 2018.
    • Tcheng, James E. Optimizing Strategies for Clinical Decision Support Summary of a Meeting Series, 2017.
    • Tcheng, James. Primary Angioplasty in Acute Myocardial Infarction. Humana Press, 2010.
    • Tcheng, James E. Primary Angioplasty in Acute Myocardial Infarction. Springer Science & Business Media, 2002.

  • Academic Articles

    • Reading Turchioe, Meghan, Alexander Volodarskiy, Jyotishman Pathak, Drew N. Wright, James Enlou Tcheng, and David Slotwiner. “Systematic review of current natural language processing methods and applications in cardiology.” Heart 108, no. 12 (May 25, 2022): 909–16. https://doi.org/10.1136/heartjnl-2021-319769.
       Full Text  Link to Item
    • Ijioma, Nkechinyere N., Creighton Don, Vishal Arora, Laura Edgar, Beau Hawkins, Peter Monteleone, James E. Tcheng, and Tarek Helmy. “ACGME Interventional Cardiology Milestones 2.0-an overview: Endorsed by the Accreditation Council for Graduate Medical Education.” Catheter Cardiovasc Interv 99, no. 3 (February 2022): 777–85. https://doi.org/10.1002/ccd.29975.
       Full Text  Link to Item
    • Windle, John R., Thomas A. Windle, Ketemwabi Y. Shamavu, Quinn M. Nelson, Martina A. Clarke, Ann L. Fruhling, and James E. Tcheng. “Roadmap to a more useful and usable electronic health record.” Cardiovasc Digit Health J 2, no. 6 (December 2021): 301–11. https://doi.org/10.1016/j.cvdhj.2021.09.007.
       Full Text  Link to Item
    • Roth, Christopher J., David A. Clunie, David J. Vining, Seth J. Berkowitz, Alejandro Berlin, Jean-Pierre Bissonnette, Shawn D. Clark, et al. “Multispecialty Enterprise Imaging Workgroup Consensus on Interactive Multimedia Reporting Current State and Road to the Future: HIMSS-SIIM Collaborative White Paper.” J Digit Imaging 34, no. 3 (June 2021): 495–522. https://doi.org/10.1007/s10278-021-00450-5.
       Full Text  Link to Item
    • Bertges, Daniel J., Roseann White, Yu-Ching Cheng, Tianyi Sun, Niveditta Ramkumar, Philip P. Goodney, Rebecca W. Wilgus, et al. “Registry Assessment of Peripheral Interventional Devices objective performance goals for superficial femoral and popliteal artery peripheral vascular interventions.” J Vasc Surg 73, no. 5 (May 2021): 1702-1714.e11. https://doi.org/10.1016/j.jvs.2020.09.030.
       Full Text  Link to Item
    • Mikita, J Stephen, Jules Mitchel, Nicolle M. Gatto, John Laschinger, James E. Tcheng, Emily P. Zeitler, Arlene S. Swern, et al. “Determining the Suitability of Registries for Embedding Clinical Trials in the United States: A Project of the Clinical Trials Transformation Initiative.” Ther Innov Regul Sci 55, no. 1 (January 2021): 6–18. https://doi.org/10.1007/s43441-020-00185-5.
       Full Text  Link to Item
    • Tcheng, James E., Miriam V. Nguyen, Helen W. Brann, Patricia A. Clarke, Maureen Pfeiffer, Jane R. Pleasants, Gregory W. Shelton, and Joseph F. Kelly. “The Medical Device Unique Device Identifier as the Single Source of Truth in Healthcare Enterprises - Roadmap for Implementation of the Clinically Integrated Supply Chain.” Med Devices (Auckl) 14 (2021): 459–67. https://doi.org/10.2147/MDER.S344132.
       Full Text  Link to Item
    • Wilson, Natalia A., James E. Tcheng, Jove Graham, and Joseph P. Drozda. “Advancing Patient Safety Surrounding Medical Devices: A Health System Roadmap to Implement Unique Device Identification at the Point of Care.” Med Devices (Auckl) 14 (2021): 411–21. https://doi.org/10.2147/MDER.S339232.
       Full Text  Link to Item
    • Tcheng, James E., Michael Gibson, Mitchell W. Krucoff, Manesh R. Patel, Mullasari Ajit, Jagdish Hiremath, Chandrashekhar Ponde, et al. “SUPPORT-1 (Subjects Undergoing PCI and Perioperative Reperfusion Treatment): A Prospective, Randomized Trial of CMX-2043 in Patients Undergoing Elective Percutaneous Coronary Intervention.” J Cardiovasc Pharmacol 76, no. 2 (August 2020): 189–96. https://doi.org/10.1097/FJC.0000000000000830.
       Full Text  Link to Item
    • Wosik, Jedrek, Marat Fudim, Blake Cameron, Ziad F. Gellad, Alex Cho, Donna Phinney, Simon Curtis, et al. “Telehealth transformation: COVID-19 and the rise of virtual care.” J Am Med Inform Assoc 27, no. 6 (June 1, 2020): 957–62. https://doi.org/10.1093/jamia/ocaa067.
       Full Text  Open Access Copy  Link to Item
    • Tcheng, James E., Rachael Fleurence, and Art Sedrakyan. “Electronic health data quality maturity model for medical device evaluations.” Bmj Surg Interv Health Technol 2, no. 1 (2020): e000043. https://doi.org/10.1136/bmjsit-2020-000043.
       Full Text  Link to Item
    • Lowenstern, Angela, Jingjing Wu, Steven M. Bradley, Alexander C. Fanaroff, James E. Tcheng, and Tracy Y. Wang. “Current landscape of hybrid revascularization: A report from the NCDR CathPCI Registry.” Am Heart J 215 (September 2019): 167–77. https://doi.org/10.1016/j.ahj.2019.06.014.
       Full Text  Link to Item
    • Slotwiner, David J., Robert L. Abraham, Sana M. Al-Khatib, H Vernon Anderson, T Jared Bunch, Martha G. Ferrara, Neal Lippman, et al. “HRS White Paper on interoperability of data from cardiac implantable electronic devices (CIEDs).” Heart Rhythm 16, no. 9 (September 2019): e107–27. https://doi.org/10.1016/j.hrthm.2019.05.002.
       Full Text  Link to Item
    • Writing Committee Members, William S., Pamela S. Douglas, Blase A. Carabello, Roberto M. Lang, Leo Lopez, Patricia A. Pellikka, Michael H. Picard, et al. “2019 ACC/AHA/ASE Key Data Elements and Definitions for Transthoracic Echocardiography: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Transthoracic Echocardiography) and the American Society of Echocardiography.” J Am Soc Echocardiogr 32, no. 9 (September 2019): 1161–1248. https://doi.org/10.1016/j.echo.2019.05.006.
       Full Text  Link to Item
    • Westcott, R Jeffrey, and James E. Tcheng. “Artificial Intelligence and Machine Learning in Cardiology.” Jacc Cardiovasc Interv 12, no. 14 (July 22, 2019): 1312–14. https://doi.org/10.1016/j.jcin.2019.03.026.
       Full Text  Link to Item
    • Douglas, Pamela S., Blase A. Carabello, Roberto M. Lang, Leo Lopez, Patricia A. Pellikka, Michael H. Picard, James D. Thomas, et al. “2019 ACC/AHA/ASE Key Data Elements and Definitions for Transthoracic Echocardiography: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards) and the American Society of Echocardiography.” Circ Cardiovasc Imaging 12, no. 7 (July 2019): e000027. https://doi.org/10.1161/HCI.0000000000000027.
       Full Text  Link to Item
    • Denardo, Scott J., Keith E. Davis, and James E. Tcheng. “Pursuit of the Optimal Antithrombotic Regimen for Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Who Undergo Subsequent Percutaneous Coronary Intervention.” Am J Cardiol 123, no. 10 (May 15, 2019): 1736. https://doi.org/10.1016/j.amjcard.2019.02.036.
       Full Text  Link to Item
    • Tcheng, James E., Joseph P. Drozda, Davera Gabriel, Anne Heath, Rebecca W. Wilgus, Mary Williams, Thomas A. Windle, and John R. Windle. “Achieving Data Liquidity: Lessons Learned from Analysis of 38 Clinical Registries (The Duke-Pew Data Interoperability Project.” Amia Annu Symp Proc 2019 (2019): 864–73.
       Open Access Copy  Link to Item
    • Valentine, C Michael, James E. Tcheng, and Thad Waites. “Translating the Translation: What Clinicians Should Know About the Fourth Universal Definition of Myocardial Infarction.” J Am Coll Cardiol 72, no. 21 (November 27, 2018): 2668–70. https://doi.org/10.1016/j.jacc.2018.10.015.
       Full Text  Link to Item
    • Hicks, Karen A., Kenneth W. Mahaffey, Roxana Mehran, Steven E. Nissen, Stephen D. Wiviott, Billy Dunn, Scott D. Solomon, et al. “2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials.” J Am Coll Cardiol 71, no. 9 (March 6, 2018): 1021–34. https://doi.org/10.1016/j.jacc.2017.12.048.
       Full Text  Link to Item
    • Hicks, Karen A., Kenneth W. Mahaffey, Roxana Mehran, Steven E. Nissen, Stephen D. Wiviott, Billy Dunn, Scott D. Solomon, et al. “2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials.” Circulation 137, no. 9 (February 27, 2018): 961–72. https://doi.org/10.1161/CIRCULATIONAHA.117.033502.
       Full Text  Link to Item
    • Drozda, Joseph P., James Roach, Thomas Forsyth, Paul Helmering, Benjamin Dummitt, and James E. Tcheng. “Constructing the informatics and information technology foundations of a medical device evaluation system: a report from the FDA unique device identifier demonstration.” J Am Med Inform Assoc 25, no. 2 (February 1, 2018): 111–20. https://doi.org/10.1093/jamia/ocx041.
       Full Text  Link to Item
    • Jones, W Schuyler, Mitchell W. Krucoff, Pablo Morales, Rebecca W. Wilgus, Anne H. Heath, Mary F. Williams, James E. Tcheng, et al. “Registry Assessment of Peripheral Interventional Devices (RAPID): Registry assessment of peripheral interventional devices core data elements.” J Vasc Surg 67, no. 2 (February 2018): 637-644.e30. https://doi.org/10.1016/j.jvs.2017.07.141.
       Full Text  Link to Item
    • O’Connor, Christopher M., Mitchell A. Psotka, Mona Fiuzat, JoAnn Lindenfeld, William T. Abraham, Michael R. Bristow, Daniel Canos, et al. “Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory.” J Am Coll Cardiol 71, no. 4 (January 30, 2018): 443–53. https://doi.org/10.1016/j.jacc.2017.11.048.
       Full Text  Link to Item
    • Jones, W Schuyler, Mitchell W. Krucoff, Pablo Morales, Rebecca W. Wilgus, Anne H. Heath, Mary F. Williams, James E. Tcheng, et al. “Registry Assessment of Peripheral Interventional Devices (RAPID)　- Registry Assessment of Peripheral Interventional Devices Core Data Elements.” Circ J 82, no. 2 (January 25, 2018): 316–22. https://doi.org/10.1253/circj.CJ-17-1156.
       Full Text  Link to Item
    • Reed, Terrie L., Joseph P. Drozda, Kevin M. Baskin, James Tcheng, Karen Conway, Natalia Wilson, Danica Marinac-Dabic, Theodore Heise, and Mitchell W. Krucoff. “Advancing medical device innovation through collaboration and coordination of structured data capture pilots: Report from the Medical Device Epidemiology Network (MDEpiNet) Specific, Measurable, Achievable, Results-Oriented, Time Bound (SMART) Think Tank.” Healthc (Amst) 5, no. 4 (December 2017): 158–64. https://doi.org/10.1016/j.hjdsi.2016.10.004.
       Full Text  Link to Item
    • Tcheng, James E. “RESPONSE: Enabling the Learning Health System, One FIT at a Time.” Journal of the American College of Cardiology 70, no. 19 (November 1, 2017): 2454–2454.
       Link to Item
    • Goyal, Abhinav, Tyler J. Gluckman, and James E. Tcheng. “What's in a Name? The New ICD-10 (10th Revision of the International Statistical Classification of Diseases and Related Health Problems) Codes and Type 2 Myocardial Infarction.” Circulation 136, no. 13 (September 26, 2017): 1180–82. https://doi.org/10.1161/CIRCULATIONAHA.117.030347.
       Full Text  Link to Item
    • Boris, Jeffrey R., Marie J. Béland, Lisa J. Bergensen, Steven D. Colan, Joanna Dangel, Curtis J. Daniels, Christopher Davis, et al. “2017 AHA/ACC Key Data Elements and Definitions for Ambulatory Electronic Health Records in Pediatric and Congenital Cardiology: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards.” J Am Coll Cardiol 70, no. 8 (August 22, 2017): 1029–95. https://doi.org/10.1016/j.jacc.2017.06.027.
       Full Text  Link to Item
    • Boris, Jeffrey R., Marie J. Beland, Lisa J. Bergensen, Steven D. Colan, Joanna Dangel, Curtis J. Daniels, Christopher Davis, et al. “2017 AHA/ACC Key Data Elements and Definitions for Ambulatory Electronic Health Records in Pediatric and Congenital Cardiology A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards.” Circulation Cardiovascular Quality and Outcomes 10, no. 8 (August 1, 2017): 1-+.
       Link to Item
    • Doll, Jacob A., Robert Overton, Manesh R. Patel, Sunil V. Rao, Michael H. Sketch, J Kevin Harrison, and James E. Tcheng. “Morbidity and Mortality Conference for Percutaneous Coronary Intervention.” Circ Cardiovasc Qual Outcomes 10, no. 8 (August 2017). https://doi.org/10.1161/CIRCOUTCOMES.116.003538.
       Full Text  Link to Item
    • Maddox, Thomas M., Nancy M. Albert, William B. Borden, Lesley H. Curtis, T Bruce Ferguson, David P. Kao, Gregory M. Marcus, et al. “The Learning Healthcare System and Cardiovascular Care: A Scientific Statement From the American Heart Association.” Circulation 135, no. 14 (April 2017): e826–57. https://doi.org/10.1161/cir.0000000000000480.
       Full Text
    • Windle, John R., Alan S. Katz, J Paul Dow, Edward T. A. Fry, Andrew M. Keller, Terran Lamp, Alexander Lippitt, et al. “2016 ACC/ASE/ASNC/HRS/SCAI Health Policy Statement on Integrating the Healthcare Enterprise.” J Am Coll Cardiol 68, no. 12 (September 20, 2016): 1348–64. https://doi.org/10.1016/j.jacc.2016.04.017.
       Full Text  Link to Item
    • Baber, Usman, Gennaro Giustino, Tracy Wang, Cindy Grines, Lisa A. McCoy, Paramita Saha-Chaudhuri, Patricia Best, et al. “Comparisons of the uptake and in-hospital outcomes associated with second-generation drug-eluting stents between men and women: results from the CathPCI Registry.” Coron Artery Dis 27, no. 6 (September 2016): 442–48. https://doi.org/10.1097/MCA.0000000000000376.
       Full Text  Link to Item
    • Denardo, Scott J., David M. Vock, Carsten M. Schmalfuss, Gregory D. Young, James E. Tcheng, and Christopher M. O’Connor. “Baseline Hemodynamics and Response to Contrast Media During Diagnostic Cardiac Catheterization Predict Adverse Events in Heart Failure Patients.” Circ Heart Fail 9, no. 7 (July 2016). https://doi.org/10.1161/CIRCHEARTFAILURE.115.002529.
       Full Text  Link to Item
    • Hall, Jennifer L., John J. Ryan, Bruce E. Bray, Candice Brown, David Lanfear, L Kristin Newby, Mary V. Relling, et al. “Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association.” Circ Cardiovasc Genet 9, no. 2 (April 2016): 193–202. https://doi.org/10.1161/HCG.0000000000000029.
       Full Text  Link to Item
    • Zeitler, Emily P., Sana M. Al-Khatib, Joseph P. Drozda, Larry G. Kessler, Ajay J. Kirtane, David F. Kong, John Laschinger, et al. “Predictable and SuStainable Implementation of National Cardiovascular Registries (PASSION) infrastructure: A think tank report from Medical Device Epidemiological Network Initiative (MDEpiNet).” Am Heart J 171, no. 1 (January 2016): 64-72.e1-2. https://doi.org/10.1016/j.ahj.2015.07.029.
       Full Text  Link to Item
    • Kansara, Pranav, Sandra Weiss, William S. Weintraub, Matthew C. Hann, James Tcheng, S Tanveer Rab, Lloyd W. Klein, and Lloyd W. Interventional Council of the American College of Cardiology. “Clinical Trials Versus Clinical Practice: When Evidence and Practice Diverge--Should Nondiabetic Patients With 3-Vessel Disease and Stable Ischemic Heart Disease Be Preferentially Treated With CABG?” Jacc Cardiovasc Interv 8, no. 13 (November 2015): 1647–56. https://doi.org/10.1016/j.jcin.2015.07.020.
       Full Text  Link to Item
    • Hicks, Karen A., James E. Tcheng, Biykem Bozkurt, Bernard R. Chaitman, Donald E. Cutlip, Andrew Farb, Gregg C. Fonarow, et al. “2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).” J Nucl Cardiol 22, no. 5 (October 2015): 1041–1144. https://doi.org/10.1007/s12350-015-0209-1.
       Full Text  Link to Item
    • Hicks, K. A., J. E. Tcheng, B. Bozkurt, B. R. Chaitman, D. E. Cutlip, A. Farb, G. C. Fonarow, et al. “Erratum: 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards) (J Am Coll Cardiol 66 (403-469)).” Journal of the American College of Cardiology 66, no. 8 (August 25, 2015). https://doi.org/10.1016/j.jacc.2015.07.004.
       Full Text
    • Hicks, Karen A., James E. Tcheng, Biykem Bozkurt, Bernard R. Chaitman, Donald E. Cutlip, Andrew Farb, Gregg C. Fonarow, et al. “2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).” J Am Coll Cardiol 66, no. 4 (July 28, 2015): 403–69. https://doi.org/10.1016/j.jacc.2014.12.018.
       Full Text  Link to Item
    • Hicks, Karen A., James E. Tcheng, Biykem Bozkurt, Bernard R. Chaitman, Donald E. Cutlip, Andrew Farb, Gregg C. Fonarow, et al. “2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).” Circulation 132, no. 4 (July 28, 2015): 302–61. https://doi.org/10.1161/CIR.0000000000000156.
       Full Text  Link to Item
    • Hess, Connie N., Matthew T. Roe, Robert M. Clare, Karen Chiswell, Joseph Kelly, James E. Tcheng, Emil Hagstrom, et al. “Relationship Between Cancer and Cardiovascular Outcomes Following Percutaneous Coronary Intervention.” J Am Heart Assoc 4, no. 7 (July 6, 2015). https://doi.org/10.1161/JAHA.115.001779.
       Full Text  Open Access Copy  Link to Item
    • Sabol, Mary Elizabeth, John Finkle, Mitch Krucoff, Norman Stockbridge, Nancy Parkhill, Kaori Shinagawa, Kenneth Mahaffey, et al. “Cardiac Safety Research Consortium (CSRC): Cardiovascular Safety and Adverse Event Case Report Forms.” Ther Innov Regul Sci 49, no. 4 (July 2015): 511–13. https://doi.org/10.1177/2168479014567319.
       Full Text  Link to Item
    • Patel, M. R., M. S. Conte, D. E. Cutlip, N. Dib, P. Geraghty, W. Gray, W. R. Hiatt, et al. “Erratum: Evaluation and treatment of patients with lower extremity peripheral artery disease: Consensus definitions from Peripheral Academic Research Consortium (PARC) (Journal of the American College of Cardiology (2015) 65:(931-41)).” Journal of the American College of Cardiology 65, no. 23 (June 16, 2015): 2578–79. https://doi.org/10.1016/j.jacc.2015.04.049.
       Full Text
    • Patel, Manesh R., Michael S. Conte, Donald E. Cutlip, Nabil Dib, Patrick Geraghty, William Gray, William R. Hiatt, et al. “Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC).” J Am Coll Cardiol 65, no. 9 (March 10, 2015): 931–41. https://doi.org/10.1016/j.jacc.2014.12.036.
       Full Text  Link to Item
    • Sherwood, Matthew W., and James E. Tcheng. “Eptifibatide in coronary intervention: past time for the next chapter.” Circ Cardiovasc Interv 8, no. 2 (February 2015): e002340. https://doi.org/10.1161/CIRCINTERVENTIONS.115.002340.
       Full Text  Link to Item
    • Tcheng, James E., Jay Crowley, Madris Tomes, Terrie L. Reed, Joseph M. Dudas, Kweli P. Thompson, Kirk N. Garratt, Joseph P. Drozda, and Joseph P. MDEpiNet UDI Demonstration Expert Workgroup. “Unique device identifiers for coronary stent postmarket surveillance and research: a report from the Food and Drug Administration Medical Device Epidemiology Network Unique Device Identifier demonstration.” Am Heart J 168, no. 4 (October 2014): 405-413.e2. https://doi.org/10.1016/j.ahj.2014.07.001.
       Full Text  Link to Item
    • Ting, H. H., E. R. Bates, M. E. Beliveau, J. P. Drozda, J. G. Harold, H. M. Krumholz, R. A. Nishimura, W. J. Oetgen, J. B. Sibley, and J. E. Tcheng. “Erratum: Update on the American Board of Internal Medicine Maintenance of Certification Program: A Report of the American College of Cardiologys Educational Quality Review Board (Journal of the American College of Cardiology (2014) 63 (92-100)).” Journal of the American College of Cardiology 63, no. 25 PART A (July 1, 2014): 2887–88. https://doi.org/10.1016/j.jacc.2014.02.523.
       Full Text
    • Sanborn, Timothy A., James E. Tcheng, H Vernon Anderson, Charles E. Chambers, Sharon L. Cheatham, Matthew V. DeCaro, Jeremy C. Durack, et al. “ACC/AHA/SCAI 2014 health policy statement on structured reporting for the cardiac catheterization laboratory: a report of the American College of Cardiology Clinical Quality Committee.” J Am Coll Cardiol 63, no. 23 (June 17, 2014): 2591–2623. https://doi.org/10.1016/j.jacc.2014.03.020.
       Full Text  Link to Item
    • Sanborn, Timothy A., James E. Tcheng, H Vernon Anderson, Charles E. Chambers, Sharon L. Cheatham, Matthew V. DeCaro, Jeremy C. Durack, et al. “ACC/AHA/SCAI 2014 health policy statement on structured reporting for the cardiac catheterization laboratory: a report of the American College of Cardiology Clinical Quality Committee.” Circulation 129, no. 24 (June 17, 2014): 2578–2609. https://doi.org/10.1161/CIR.0000000000000043.
       Full Text  Link to Item
    • Hendel, Robert C., Biykem Bozkurt, Gregg C. Fonarow, Jeffrey P. Jacobs, Judith H. Lichtman, Eric E. Smith, James E. Tcheng, Tracy Y. Wang, and William S. Weintraub. “ACC/AHA 2013 methodology for developing clinical data standards: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards.” J Am Coll Cardiol 63, no. 21 (June 3, 2014): 2323–34. https://doi.org/10.1016/j.jacc.2013.11.006.
       Full Text  Link to Item
    • Hendel, Robert C., Biykem Bozkurt, Gregg C. Fonarow, Jeffrey P. Jacobs, Judith H. Lichtman, Eric E. Smith, James E. Tcheng, Tracy Y. Wang, and William S. Weintraub. “ACC/AHA 2013 methodology for developing clinical data standards: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards.” Circulation 129, no. 22 (June 3, 2014): 2346–57. https://doi.org/10.1161/01.cir.0000438353.32328.98.
       Full Text  Link to Item
    • Ting, Henry H., Eric R. Bates, Mary Ellen Beliveau, Joseph P. Drozda, John Gordon Harold, Harlan M. Krumholz, Rick A. Nishimura, William J. Oetgen, Janice B. Sibley, and James E. Tcheng. “Update on the American Board of Internal Medicine Maintenance of Certification Program: a report of the American College of Cardiology's Educational Quality Review Board.” J Am Coll Cardiol 63, no. 1 (January 7, 2014): 92–100. https://doi.org/10.1016/j.jacc.2013.10.002.
       Full Text  Link to Item
    • Denardo, Scott J., Paul L. Carpinone, David M. Vock, James E. Tcheng, Harry R. Phillips, Bradley J. Willenberg, Christopher D. Batich, and Carl J. Pepine. “Detailed analysis of polymer response to delivery balloon expansion of drug-eluting stents versus bare metal stents.” Eurointervention 9, no. 3 (July 2013): 389–97. https://doi.org/10.4244/EIJV9I3A62.
       Full Text  Link to Item
    • Cannon, Christopher P., Ralph G. Brindis, Bernard R. Chaitman, David J. Cohen, J Thomas Cross, Joseph P. Drozda, Francis M. Fesmire, et al. “2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards).” Crit Pathw Cardiol 12, no. 2 (June 2013): 65–105. https://doi.org/10.1097/HPC.0b013e3182846e16.
       Full Text  Link to Item
    • Mehta, Rajendra H., Kishore J. Harjai, Judy A. Boura, James E. Tcheng, Simon R. Dixon, Gregg W. Stone, and Cindy L. Grines. “Short-term outcomes of balloon angioplasty versus stent placement for patients undergoing primary percutaneous coronary intervention: Implications for patients requiring early coronary artery bypass surgery.” Am Heart J 165, no. 6 (June 2013): 1000–1007. https://doi.org/10.1016/j.ahj.2013.03.006.
       Full Text  Link to Item
    • Anderson, H Vernon, William S. Weintraub, Martha J. Radford, Mark S. Kremers, Matthew T. Roe, Richard E. Shaw, Dana M. Pinchotti, and James E. Tcheng. “Standardized cardiovascular data for clinical research, registries, and patient care: a report from the Data Standards Workgroup of the National Cardiovascular Research Infrastructure project.” J Am Coll Cardiol 61, no. 18 (May 7, 2013): 1835–46. https://doi.org/10.1016/j.jacc.2012.12.047.
       Full Text  Link to Item
    • Cannon, Christopher P., Ralph G. Brindis, Bernard R. Chaitman, David J. Cohen, J Thomas Cross, Joseph P. Drozda, Francis M. Fesmire, et al. “2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on clinical data standards (writing committee to develop acute coronary syndromes and coronary artery disease clinical data standards).” J Am Coll Cardiol 61, no. 9 (March 5, 2013): 992–1025. https://doi.org/10.1016/j.jacc.2012.10.005.
       Full Text  Link to Item
    • Snyder, Denise C., Shelly Epps, Henry F. Beresford, Cory Ennis, Justin S. Levens, Stephen K. Woody, James E. Tcheng, Mark A. Stacy, and Meredith Nahm. “Research management team (RMT): a model for research support services at Duke University.” Clin Transl Sci 5, no. 6 (December 2012): 464–69. https://doi.org/10.1111/cts.12010.
       Full Text  Link to Item
    • Jolicoeur, E Marc, Micheal J. Sketch, Manesh R. Patel, and James E. Tcheng. “Rebuttal: the CTO "no-controversy" controversy: should the field of CTO-PCI be allowed to expand?” Catheter Cardiovasc Interv 80, no. 1 (July 1, 2012): 154–55. https://doi.org/10.1002/ccd.24282.
       Full Text  Link to Item
    • Murphy, Shawn N., Anil Dubey, Peter J. Embi, Paul A. Harris, Brent G. Richter, Fran Turisco, Griffin M. Weber, James E. Tcheng, and Diane Keogh. “Current state of information technologies for the clinical research enterprise across academic medical centers.” Clin Transl Sci 5, no. 3 (June 2012): 281–84. https://doi.org/10.1111/j.1752-8062.2011.00387.x.
       Full Text  Link to Item
    • Tcheng, James E., and Steven M. Mackay. “Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.” Am J Cardiovasc Drugs 12, no. 2 (April 1, 2012): 83–91. https://doi.org/10.2165/11594600-000000000-00000.
       Full Text  Link to Item
    • Mehta, Rajendra H., Jennifer Yu, Jonathan P. Piccini, James E. Tcheng, Michael E. Farkouh, James Reiffel, Martin Fahy, Roxana Mehran, and Gregg W. Stone. “Prognostic significance of postprocedural sustained ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention (from the HORIZONS-AMI Trial).” Am J Cardiol 109, no. 6 (March 15, 2012): 805–12. https://doi.org/10.1016/j.amjcard.2011.10.043.
       Full Text  Link to Item
    • Jolicœur, E Marc, Micheal J. Sketch, Daniel M. Wojdyla, Sean P. Javaheri, Shravan Nosib, Yuliya Lokhnygina, Manesh R. Patel, Linda K. Shaw, and James E. Tcheng. “Percutaneous coronary interventions and cardiovascular outcomes for patients with chronic total occlusions.” Catheter Cardiovasc Interv 79, no. 4 (March 1, 2012): 603–12. https://doi.org/10.1002/ccd.23269.
       Full Text  Link to Item
    • Creager, Mark A., Michael Belkin, Edward I. Bluth, Donald E. Casey, Seemant Chaturvedi, Michael D. Dake, Jerome L. Fleg, et al. “2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN/SVS Key data elements and definitions for peripheral atherosclerotic vascular disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to develop Clinical Data Standards for peripheral atherosclerotic vascular disease).” J Am Coll Cardiol 59, no. 3 (January 17, 2012): 294–357. https://doi.org/10.1016/j.jacc.2011.10.860.
       Full Text  Link to Item
    • Writing Committee to Develop Clinical Data Standards for Peripheral Atherosclerotic Vascular Disease, William S., Mark A. Creager, Michael Belkin, Edward I. Bluth, Donald E. Casey, Seemant Chaturvedi, Michael D. Dake, et al. “2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN/SVS key data elements and definitions for peripheral atherosclerotic vascular disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Peripheral Atherosclerotic Vascular Disease).” Circulation 125, no. 2 (January 17, 2012): 395–467. https://doi.org/10.1161/CIR.0b013e31823299a1.
       Full Text  Link to Item
    • Denardo, Scott J., David M. Vock, Carsten M. Schmalfuss, Gregory D. Young, James E. Tcheng, Melvin R. Echols, Karen S. Pieper, and Christopher M. O’Connor. “Baseline Hemodynamics with Cardiac Performance Response to Contrast Media During Diagnostic Cardiac Catheterization Enhances Prediction of Adverse Events in Heart Failure Patients.” Circulation 124, no. 21 (November 22, 2011).
       Link to Item
    • Weintraub, William S., Ronald P. Karlsberg, James E. Tcheng, Jeffrey R. Boris, Alfred E. Buxton, James T. Dove, Gregg C. Fonarow, et al. “ACCF/AHA 2011 key data elements and definitions of a base cardiovascular vocabulary for electronic health records: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards.” J Am Coll Cardiol 58, no. 2 (July 5, 2011): 202–22. https://doi.org/10.1016/j.jacc.2011.05.001.
       Full Text  Link to Item
    • Weintraub, William S., Ronald P. Karlsberg, James E. Tcheng, Jeffrey R. Boris, Alfred E. Buxton, James T. Dove, Gregg C. Fonarow, et al. “ACCF/AHA 2011 key data elements and definitions of a base cardiovascular vocabulary for electronic health records: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards.” Circulation 124, no. 1 (July 5, 2011): 103–23. https://doi.org/10.1161/CIR.0b013e31821ccf71.
       Full Text  Link to Item
    • Segall, Noa, Jeffrey G. Saville, Pete L’Engle, Boyd Carlson, Melanie C. Wright, Kevin Schulman, and James E. Tcheng. “Usability evaluation of a personal health record.” Amia Annu Symp Proc 2011 (2011): 1233–42.
       Link to Item
    • Walden, Anita, Meredith Nahm, M Edwina Barnett, Jose G. Conde, Andrew Dent, Ahmed Fadiel, Theresa Perry, Chris Tolk, James E. Tcheng, and Eric L. Eisenstein. “Economic analysis of centralized vs. decentralized electronic data capture in multi-center clinical studies.” Stud Health Technol Inform 164 (2011): 82–88.
       Link to Item
    • Sorajja, Paul, Bernard J. Gersh, David A. Cox, Michael G. McLaughlin, Peter Zimetbaum, Costantino Costantini, Thomas Stuckey, et al. “Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.” J Am Coll Cardiol 55, no. 14 (April 6, 2010): 1416–24. https://doi.org/10.1016/j.jacc.2009.11.063.
       Full Text  Link to Item
    • Deibele, Albert J., Lisa K. Jennings, James E. Tcheng, Cathy Neva, Angela D. Earhart, and C Michael Gibson. “Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.” Circulation 121, no. 6 (February 16, 2010): 784–91. https://doi.org/10.1161/CIRCULATIONAHA.109.882746.
       Full Text  Link to Item
    • Kruk, Mariusz, Christopher E. Buller, James Enlou Tcheng, Vladimir Dzavík, Venugopal Menon, GB John Mancini, Sandra A. Forman, et al. “Impact of left ventricular ejection fraction on clinical outcomes over five years after infarct-related coronary artery recanalization (from the Occluded Artery Trial [OAT]).” Am J Cardiol 105, no. 1 (January 1, 2010): 10–16. https://doi.org/10.1016/j.amjcard.2009.08.644.
       Full Text  Link to Item
    • Tcheng, James E., and David A. Zidar. “Gone but not forgotten: the case for drug-eluting stents in percutaneous revascularization of the chronic coronary total occlusion.” Jacc Cardiovasc Interv 2, no. 12 (December 2009): 1266–68. https://doi.org/10.1016/j.jcin.2009.10.007.
       Full Text  Link to Item
    • Guerra, Daniel R., and James E. Tcheng. “Prasugrel: Clinical development and therapeutic application.” Adv Ther 26, no. 11 (November 2009): 999–1011. https://doi.org/10.1007/s12325-009-0081-y.
       Full Text  Link to Item
    • Madan, Mina, Janarthan Nikhil, Anne S. Hellkamp, Karen S. Pieper, Marino Labinaz, E. A. Cohen, Christopher E. Buller, et al. “Effect of operator and institutional volume on clinical outcomes after percutaneous coronary interventions performed in Canada and the United States: a brief report from the Enhanced Suppression of the Platelet glycoprotein IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) study.” Can J Cardiol 25, no. 8 (August 2009): e269–72. https://doi.org/10.1016/s0828-282x(09)70120-5.
       Full Text  Link to Item
    • Rabbani, Leroy E., Srinivas Iyengar, George D. Dangas, Cindy L. Grines, David A. Cox, Eulogio Garcia, James E. Tcheng, et al. “Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction.” J Interv Cardiol 22, no. 4 (August 2009): 378–84. https://doi.org/10.1111/j.1540-8183.2009.00474.x.
       Full Text  Link to Item
    • Nikolsky, Eugenia, Roxana Mehran, H Mehrdad Sadeghi, Cindy L. Grines, David A. Cox, Eulogio Garcia, James E. Tcheng, et al. “Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial.” Jacc Cardiovasc Interv 2, no. 7 (July 2009): 624–32. https://doi.org/10.1016/j.jcin.2009.05.004.
       Full Text  Link to Item
    • Denardo, Scott J., Mustafa H. M. Hassan, Richard S. Schofield, James A. Hill, Keith E. Davis, and James E. Tcheng. “Percutaneous Coronary Intervention for Treatment of Symptomatic Ischemic Heart Failure With Normal Left Ventricular Systolic Function.” Journal of the American College of Cardiology 53, no. 10 (March 10, 2009): A51–A51.
       Link to Item
    • Tcheng, James E., Ing Haan Lim, Shankar Srinivasan, Joseph Jozic, C Michael Gibson, J Conor O’Shea, Joseph A. Puma, and Daniel I. Simon. “Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trial.” Circ Cardiovasc Interv 2, no. 1 (February 2009): 43–51. https://doi.org/10.1161/CIRCINTERVENTIONS.108.809285.
       Full Text  Link to Item
    • Lansky, Alexandra J., Yoshihiro Tsuchiya, Micheal Brener, Roxana Mehran, Ecaterina Cristea, Cody Pietras, Cindy L. Grines, et al. “Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial.” Catheter Cardiovasc Interv 72, no. 7 (December 1, 2008): 917–24. https://doi.org/10.1002/ccd.21714.
       Full Text  Link to Item
    • Kruk, M., C. E. Buller, V. Dzavik, G. B. J. Mancini, P. Kurray, J. E. Tcheng, V. Menon, S. A. Forman, G. A. Lamas, and J. S. Hochman. “Late recanalization of infarct related artery has no impact on clinical outcomes regardless of ejection fraction: Results from the Occluded Artery Trial (OAT).” European Heart Journal 29 (September 1, 2008): 679–679.
       Link to Item
    • Casterella, Peter J., and James E. Tcheng. “Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: practical implications, new clinical data, and recommended guideline revisions.” Am Heart J 155, no. 5 (May 2008): 781–90. https://doi.org/10.1016/j.ahj.2007.12.014.
       Full Text  Link to Item
    • Novaro, Gian M., Craig R. Asher, Deepak L. Bhatt, David J. Moliterno, Robert A. Harrington, A Michael Lincoff, L Kristin Newby, James E. Tcheng, Amy P. Hsu, and Sergio L. Pinski. “Meta-analysis comparing reported frequency of atrial fibrillation after acute coronary syndromes in Asians versus whites.” Am J Cardiol 101, no. 4 (February 15, 2008): 506–9. https://doi.org/10.1016/j.amjcard.2007.09.098.
       Full Text  Link to Item
    • Denardo, Scott J., Keith E. Davis, and James E. Tcheng. “Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention.” Am J Cardiol 100, no. 9 (November 1, 2007): 1376–82. https://doi.org/10.1016/j.amjcard.2007.06.024.
       Full Text  Link to Item
    • Dery, J., J. Griffin, K. S. Pieper, R. A. Harrington, and J. E. Tcheng. “Comparison of outcomes between patients undergoing percutaneous coronary stent implantation with eptifibatide and abciximab: An analysis using propensity score methods.” Canadian Journal of Cardiology 23 (October 1, 2007): 59C-59C.
       Link to Item
    • Dery, J. P., J. Griffin, K. S. Pieper, R. A. Harrington, and J. E. Tcheng. “Comparison of outcomes between patients undergoing percutaneous coronary stent implantation with eptifibatide and abciximab: an analysis using propensity score methods.” European Heart Journal 28 (September 1, 2007): 184–184.
       Link to Item
    • Dery, Jean-Pierre, Mark E. Campbell, Jasmine Mathias, Karen S. Pieper, Robert A. Harrington, Mina Madan, C Michael Gibson, et al. “Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.” Catheter Cardiovasc Interv 70, no. 1 (July 1, 2007): 43–50. https://doi.org/10.1002/ccd.21059.
       Full Text  Link to Item
    • Sorajja, Paul, Bernard J. Gersh, David A. Cox, Michael G. McLaughlin, Peter Zimetbaum, Costantino Costantini, Thomas Stuckey, et al. “Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction.” Eur Heart J 28, no. 14 (July 2007): 1709–16. https://doi.org/10.1093/eurheartj/ehm184.
       Full Text  Link to Item
    • Nikolsky, Eugenia, Cindy L. Grines, David A. Cox, Eulogio Garcia, James E. Tcheng, Mehrdad Sadeghi, Roxana Mehran, Alexandra J. Lansky, Yingbo Na, and Gregg W. Stone. “Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial).” Am J Cardiol 99, no. 8 (April 15, 2007): 1055–61. https://doi.org/10.1016/j.amjcard.2006.11.066.
       Full Text  Link to Item
    • Prasad, Abhiram, Gregg W. Stone, Thomas D. Stuckey, Costantino O. Costantini, Roxana Mehran, Eulogio Garcia, James E. Tcheng, et al. “Relation between leucocyte count, myonecrosis, myocardial perfusion, and outcomes following primary angioplasty.” Am J Cardiol 99, no. 8 (April 15, 2007): 1067–71. https://doi.org/10.1016/j.amjcard.2006.11.063.
       Full Text  Link to Item
    • Radford, Martha J., Paul A. Heidenreich, Steven R. Bailey, David C. Goff, Frederick L. Grover, Edward P. Havranek, Richard E. Kuntz, et al. “ACC/AHA 2007 methodology for the development of clinical data standards: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards.” J Am Coll Cardiol 49, no. 7 (February 20, 2007): 830–37. https://doi.org/10.1016/j.jacc.2007.01.002.
       Full Text  Link to Item
    • Harjai, Kishore J., Gregg W. Stone, Cindy L. Grines, David A. Cox, Eulogio Garcia, James E. Tcheng, Yingbo Na, et al. “Usefulness of routine unfractionated heparin infusion following primary percutaneous coronary intervention for acute myocardial infarction in patients not receiving glycoprotein IIb/IIIa inhibitors.” Am J Cardiol 99, no. 2 (January 15, 2007): 202–7. https://doi.org/10.1016/j.amjcard.2006.07.084.
       Full Text  Link to Item
    • Berger, Jeffrey S., John L. Petersen, James E. Tcheng, and Harry R. Phillips. “Clinical implications of vulnerable plaque.” Future Cardiol 2, no. 6 (November 2006): 721–31. https://doi.org/10.2217/14796678.2.6.721.
       Full Text  Link to Item
    • Saw, Jacqueline, Deepak L. Bhatt, David J. Moliterno, Sorin J. Brener, Steven R. Steinhubl, A Michael Lincoff, James E. Tcheng, et al. “The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials.” J Am Coll Cardiol 48, no. 8 (October 17, 2006): 1567–72. https://doi.org/10.1016/j.jacc.2006.03.067.
       Full Text  Link to Item
    • Tcheng, James E., and Kurt G. Kinney. “After fibrinolysis: is cardiac catheterization the answer?” J Am Coll Cardiol 48, no. 7 (October 3, 2006): 1336–38. https://doi.org/10.1016/j.jacc.2006.07.004.
       Full Text  Link to Item
    • Tcheng, James E. “Debate of adjunctive pharmacology for percutaneous coronary intervention: anticoagulation and clopidogrel are not (always) enough.” J Interv Cardiol 19, no. 5 (October 2006): 456–63. https://doi.org/10.1111/j.1540-8183.2006.00186.x.
       Full Text  Link to Item
    • Cox, David A., Gregg W. Stone, Cindy L. Grines, Thomas Stuckey, Peter J. Zimetbaum, James E. Tcheng, Mark Turco, et al. “Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial).” Am J Cardiol 98, no. 3 (August 1, 2006): 331–37. https://doi.org/10.1016/j.amjcard.2006.01.102.
       Full Text  Link to Item
    • Deibele, Albert J., Ajay J. Kirtane, Duane S. Pinto, Michael J. Lucca, Cathy Neva, Amy Shui, Sabina A. Murphy, James E. Tcheng, and C Michael Gibson. “Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina.” J Thromb Thrombolysis 22, no. 1 (August 2006): 47–50. https://doi.org/10.1007/s11239-006-7454-8.
       Full Text  Link to Item
    • Brodie, Bruce R., Gregg W. Stone, David A. Cox, Thomas D. Stuckey, Mark Turco, James E. Tcheng, Peter Berger, et al. “Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: analysis from the CADILLAC trial.” Am Heart J 151, no. 6 (June 2006): 1231–38. https://doi.org/10.1016/j.ahj.2005.07.016.
       Full Text  Link to Item
    • Kandzari, David E., James E. Tcheng, Bernard J. Gersh, David A. Cox, Thomas Stuckey, Mark Turco, Roxana Mehran, et al. “Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction.” Am Heart J 151, no. 6 (June 2006): 1288–95. https://doi.org/10.1016/j.ahj.2005.08.017.
       Full Text  Link to Item
    • Halkin, Amir, Gregg W. Stone, Cindy L. Grines, David A. Cox, Barry D. Rutherford, Paolo Esente, Carol M. Meils, et al. “Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction.” J Am Coll Cardiol 47, no. 5 (March 7, 2006): 951–61. https://doi.org/10.1016/j.jacc.2005.12.003.
       Full Text  Link to Item
    • Puma, Joseph A., Lesan T. Banko, Karen S. Pieper, Terrence J. Sacchi, J Conor O’Shea, Jean Pierre Dery, and James E. Tcheng. “Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.” J Am Coll Cardiol 47, no. 4 (February 21, 2006): 715–18. https://doi.org/10.1016/j.jacc.2005.08.075.
       Full Text  Link to Item
    • De Luca, Giuseppe, Harry Suryapranata, Gregg W. Stone, David Antoniucci, James E. Tcheng, Franz-Josef Neumann, Erminio Bonizzoni, Eric J. Topol, and Massimo Chiariello. “Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials.” J Am Coll Cardiol 47, no. 3 (February 7, 2006): 685–86. https://doi.org/10.1016/j.jacc.2005.11.018.
       Full Text  Link to Item
    • Musser, R Clayton, and James E. Tcheng. “Quantitative and qualitative comparison of text-based and graphical user interfaces for Computerized Provider Order Entry.” Amia Annu Symp Proc, 2006, 1041.
       Link to Item
    • Nikolsky, Eugenia, Gregg W. Stone, Cindy L. Grines, David A. Cox, Eulogio Garcia, James E. Tcheng, John J. Griffin, et al. “Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction.” Am Heart J 151, no. 1 (January 2006): 168–75. https://doi.org/10.1016/j.ahj.2005.03.024.
       Full Text  Link to Item
    • Vikoren, Thomas H., R Clayton Musser, James E. Tcheng, and James A. Nunley. “From clinical pathways to CPOE: challenges and opportunities in standardization and computerization of postoperative orders for total joint replacement.” J Surg Orthop Adv 15, no. 4 (2006): 195–200.
       Link to Item
    • Halkin, Amir, Gregg W. Stone, Cindy L. Grines, David A. Cox, Thomas D. Stuckey, Eulogio Garcia, Giulio Guagliumi, et al. “Outcomes of patients consented but not randomized in a trial of primary percutaneous coronary intervention in acute myocardial infarction (the CADILLAC registry).” Am J Cardiol 96, no. 12 (December 15, 2005): 1649–55. https://doi.org/10.1016/j.amjcard.2005.07.088.
       Full Text  Link to Item
    • Nikolsky, Eugenia, H Mehrdad Sadeghi, Mark B. Effron, Roxana Mehran, Alexandra J. Lansky, Yingbo Na, David A. Cox, et al. “Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction.” Am J Cardiol 96, no. 4 (August 15, 2005): 474–81. https://doi.org/10.1016/j.amjcard.2005.04.005.
       Full Text  Link to Item
    • Halkin, Amir, Gregg W. Stone, Simon R. Dixon, Cindy L. Grines, James E. Tcheng, David A. Cox, Eulogio Garcia, et al. “Impact and determinants of left ventricular function in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction.” Am J Cardiol 96, no. 3 (August 1, 2005): 325–31. https://doi.org/10.1016/j.amjcard.2005.03.069.
       Full Text  Link to Item
    • Weisz, Giora, David A. Cox, Eulogio Garcia, James E. Tcheng, John J. Griffin, Giulio Guagliumi, Thomas D. Stuckey, et al. “Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited.” Am Heart J 150, no. 2 (August 2005): 358–64. https://doi.org/10.1016/j.ahj.2004.01.032.
       Full Text  Link to Item
    • Tcheng, J., H. Mann, A. J. London, and J. Mann. “Equipoise in the Enhanced Supression of the Platelet IIb/IIIa Receptor with Integrilin Trial (ESPRIT): A critical appraisal. Comment.” Clinical Trials 2, no. 3 (July 13, 2005): 242–43.
    • Cantor, Warren J., Mina Madan, J Conor O’Shea, Robert J. Chisholm, Henry K. Lui, David J. Cohen, Robert L. Feldman, et al. “Bailout use of platelet glycoprotein IIb-IIIa inhibition during coronary stent implantation: observations from the ESPRIT trial.” J Invasive Cardiol 17, no. 7 (July 2005): 360–64.
       Link to Item
    • Halkin, Amir, Mandeep Singh, Eugenia Nikolsky, Cindy L. Grines, James E. Tcheng, Eulogio Garcia, David A. Cox, et al. “Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score.” J Am Coll Cardiol 45, no. 9 (May 3, 2005): 1397–1405. https://doi.org/10.1016/j.jacc.2005.01.041.
       Full Text  Link to Item
    • Paraschos, Alexander, Dwayne Callwood, Marilyn B. Wightman, James E. Tcheng, Harry R. Phillips, Gary L. Stiles, John M. Daniel, and Michael H. Sketch. “Outcomes following elective percutaneous coronary intervention without on-site surgical backup in a community hospital.” Am J Cardiol 95, no. 9 (May 1, 2005): 1091–93. https://doi.org/10.1016/j.amjcard.2004.12.066.
       Full Text  Link to Item
    • De Luca, Giuseppe, Harry Suryapranata, Gregg W. Stone, David Antoniucci, James E. Tcheng, Franz-Josef Neumann, Frans Van de Werf, Elliott M. Antman, and Eric J. Topol. “Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.” Jama 293, no. 14 (April 13, 2005): 1759–65. https://doi.org/10.1001/jama.293.14.1759.
       Full Text  Link to Item
    • Lansky, Alexandra J., Cody Pietras, Ricardo A. Costa, Yoshihiro Tsuchiya, Bruce R. Brodie, David A. Cox, Eve D. Aymong, et al. “Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.” Circulation 111, no. 13 (April 5, 2005): 1611–18. https://doi.org/10.1161/01.CIR.0000160362.55803.40.
       Full Text  Link to Item
    • Sorajja, Paul, Bernard J. Gersh, Costantino Costantini, Michael G. McLaughlin, Peter Zimetbaum, David A. Cox, Eulogio Garcia, et al. “Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction.” Eur Heart J 26, no. 7 (April 2005): 667–74. https://doi.org/10.1093/eurheartj/ehi167.
       Full Text  Link to Item
    • Exaire, J Emilio, James E. Tcheng, Dean J. Kereiakes, Neal S. Kleiman, Robert J. Applegate, David J. Moliterno, and David J. ELECT Investigators. “Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel.” Catheter Cardiovasc Interv 64, no. 3 (March 2005): 369–72. https://doi.org/10.1002/ccd.20257.
       Full Text  Link to Item
    • Prasad, Abhiram, Gregg W. Stone, Thomas D. Stuckey, Costantino O. Costantini, Peter J. Zimetbaum, Michael McLaughlin, Roxana Mehran, et al. “Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction.” J Am Coll Cardiol 45, no. 4 (February 15, 2005): 508–14. https://doi.org/10.1016/j.jacc.2004.10.054.
       Full Text  Link to Item
    • Tcheng, James E., and Steve Kindsvater. “Hospital percutaneous coronary intervention volume and outcome: does it matter?” J Interv Cardiol 18, no. 1 (February 2005): 17–19. https://doi.org/10.1111/j.1540-8183.2005.4044a.x.
       Full Text  Link to Item
    • Denardo, Scott J., Keith E. Davis, and James E. Tcheng. “Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy.” Am Heart J 149, no. 1 (January 2005): 138–44. https://doi.org/10.1016/j.ahj.2004.06.002.
       Full Text  Link to Item
    • Stuckey, Thomas D., Gregg W. Stone, David A. Cox, James E. Tcheng, Eulogio Garcia, John Carroll, Giulio Guagliumi, et al. “Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial).” Am J Cardiol 95, no. 1 (January 1, 2005): 1–7. https://doi.org/10.1016/j.amjcard.2004.08.054.
       Full Text  Link to Item
    • Tsai, Thomas T., Eduardo Bossone, Eric M. Isselbacher, Christoph A. Nienaber, Arturo Evangelista, Jianming Fang, Dean E. Smith, et al. “Clinical characteristics of hypotension in patients with acute aortic dissection.” The American Journal of Cardiology 95, no. 1 (January 2005): 48–52. https://doi.org/10.1016/j.amjcard.2004.08.062.
       Full Text
    • Halabi, Abdul R., Michael H. Sketch, James E. Tcheng, Punit Goel, Kul Aggarwal, David Ramsdale, Shahid Aziz, Rajbir S. Sangha, and Peter Y. M. Hui. “Which is the true channel?” J Invasive Cardiol 16, no. 12 (December 2004): 716–18.
       Link to Item
    • Madan, Mina, Marino Labinaz, Eric A. Cohen, Christopher E. Buller, Warren J. Cantor, Peter Seidelin, John Ducas, et al. “A comparison of clinical outcomes between Canadian and American patients after nonurgent coronary stenting.” Can J Cardiol 20, no. 13 (November 2004): 1343–49.
       Link to Item
    • Dangas, George, Eve D. Aymong, Roxana Mehran, James E. Tcheng, Cindy L. Grines, David A. Cox, Eulogio Garcia, et al. “Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial).” Am J Cardiol 94, no. 8 (October 15, 2004): 983–88. https://doi.org/10.1016/j.amjcard.2004.06.050.
       Full Text  Link to Item
    • Kandzari, David E., James E. Tcheng, Cindy L. Grines, David A. Cox, Thomas Stuckey, John J. Griffin, Mark Turco, et al. “Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction.” Am J Cardiol 94, no. 8 (October 15, 2004): 1029–33. https://doi.org/10.1016/j.amjcard.2004.06.060.
       Full Text  Link to Item
    • Rebeiz, Abdallah G., Jean-Pierre Dery, Anastasios A. Tsiatis, J Conor O’shea, Brent A. Johnson, Anne S. Hellkamp, Karen S. Pieper, et al. “Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy).” Am J Cardiol 94, no. 7 (October 1, 2004): 926–29. https://doi.org/10.1016/j.amjcard.2004.06.030.
       Full Text  Link to Item
    • Guagliumi, Giulio, Gregg W. Stone, David A. Cox, Thomas Stuckey, James E. Tcheng, Mark Turco, Giuseppe Musumeci, et al. “Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.” Circulation 110, no. 12 (September 21, 2004): 1598–1604. https://doi.org/10.1161/01.CIR.0000142862.98817.1F.
       Full Text  Link to Item
    • McLaughlin, Michael G., Gregg W. Stone, Eve Aymong, Graham Gardner, Roxana Mehran, Alexandra J. Lansky, Cindy L. Grines, et al. “Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.” J Am Coll Cardiol 44, no. 6 (September 15, 2004): 1215–23. https://doi.org/10.1016/j.jacc.2004.06.053.
       Full Text  Link to Item
    • Cantor, Warren J., James E. Tcheng, James C. Blankenship, J Conor O’Shea, Karen S. Pieper, Douglas A. Criger, Mina Madan, et al. “Temporal spectrum of ischemic complications with percutaneous coronary intervention: the ESPRIT experience.” J Invasive Cardiol 16, no. 9 (September 2004): 475–81.
       Link to Item
    • Sadeghi, H Mehrdad, Cindy L. Grines, Harish R. Chandra, Roxana Mehran, Martin Fahy, David A. Cox, Eulogio Garcia, et al. “Magnitude and impact of treatment delays on weeknights and weekends in patients undergoing primary angioplasty for acute myocardial infarction (the cadillac trial).” Am J Cardiol 94, no. 5 (September 1, 2004): 637-A9. https://doi.org/10.1016/j.amjcard.2004.05.030.
       Full Text  Link to Item
    • Nikolsky, Eugenia, Eve D. Aymong, Amir Halkin, Cindy L. Grines, David A. Cox, Eulogio Garcia, Roxana Mehran, et al. “Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial.” J Am Coll Cardiol 44, no. 3 (August 4, 2004): 547–53. https://doi.org/10.1016/j.jacc.2004.03.080.
       Full Text  Link to Item
    • Costantini, Costantino O., Gregg W. Stone, Roxana Mehran, Eve Aymong, Cindy L. Grines, David A. Cox, Thomas Stuckey, et al. “Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction.” J Am Coll Cardiol 44, no. 2 (July 21, 2004): 305–12. https://doi.org/10.1016/j.jacc.2004.03.058.
       Full Text  Link to Item
    • Rajagopal, Vivek, Hitinder S. Gurm, Deepak L. Bhatt, A Michael Lincoff, James E. Tcheng, Dean J. Kereiakes, Neal S. Kleiman, Gang Jia, and Eric J. Topol. “Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality.” Am J Cardiol 94, no. 2 (July 15, 2004): 190–92. https://doi.org/10.1016/j.amjcard.2004.03.060.
       Full Text  Link to Item
    • Gurm, Hitinder S., A Michael Lincoff, Neil S. Kleiman, Dean J. Kereiakes, James E. Tcheng, Herbert D. Aronow, Arman T. Askari, Danielle M. Brennan, and Eric J. Topol. “Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions.” Am J Cardiol 94, no. 1 (July 1, 2004): 30–34. https://doi.org/10.1016/j.amjcard.2004.03.025.
       Full Text  Link to Item
    • Halkin, Amir, Cindy L. Grines, David A. Cox, Eulogio Garcia, Roxana Mehran, James E. Tcheng, John J. Griffin, et al. “Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction.” J Am Coll Cardiol 43, no. 10 (May 19, 2004): 1780–87. https://doi.org/10.1016/j.jacc.2003.10.068.
       Full Text  Link to Item
    • Pellizzon, Gregory G., Cindy L. Grines, David A. Cox, Thomas Stuckey, James E. Tcheng, Eulogio Garcia, Giulio Guagliumi, et al. “Importance of mitral regurgitation inpatients undergoing percutaneous coronary intervention for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.” J Am Coll Cardiol 43, no. 8 (April 21, 2004): 1368–74. https://doi.org/10.1016/j.jacc.2003.11.046.
       Full Text  Link to Item
    • Dery, Jean-Pierre, Gregory A. Braden, A Michael Lincoff, Dean J. Kereiakes, Kevin Browne, Thomas Little, Barry S. George, et al. “Final results of the ReoPro readministration registry.” Am J Cardiol 93, no. 8 (April 15, 2004): 979–84. https://doi.org/10.1016/j.amjcard.2003.12.051.
       Full Text  Link to Item
    • Rozenman, Yoseph. “For how long should treatment with clopidogrel be continued after coronary stent implantation?” J Am Coll Cardiol 43, no. 7 (April 7, 2004): 1331. https://doi.org/10.1016/j.jacc.2004.01.007.
       Full Text  Link to Item
    • Konstance, Richard, James E. Tcheng, Marilyn B. Wightman, Larry P. Kelly, Annette Moore, J Kevin Harrison, and Michael H. Sketch. “Incidence and predictors of major vascular complications after percutaneous coronary intervention in the glycoprotein IIb/IIIa platelet inhibitor era.” J Interv Cardiol 17, no. 2 (April 2004): 65–70. https://doi.org/10.1111/j.1540-8183.2004.00295.x.
       Full Text  Link to Item
    • McLellan, C. S., J. C. O’Shea, J. E. Tcheng, and M. Labinaz. “Coronary artery stenting and eptifibatide treatment in diabetes.” Cardiology Review 21, no. 4 (April 1, 2004).
    • Prasad, Abhiram, Gregg W. Stone, Eve Aymong, Peter J. Zimetbaum, Michael McLaughlin, Roxana Mehran, Eulogio Garcia, et al. “Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: an analysis from the CADILLAC trial.” Am Heart J 147, no. 4 (April 2004): 669–75. https://doi.org/10.1016/j.ahj.2003.11.010.
       Full Text  Link to Item
    • Tcheng, James E. “Reply.” Journal of the American College of Cardiology 43, no. 7 (April 2004): 1331–32. https://doi.org/10.1016/j.jacc.2004.01.008.
       Full Text
    • Kandzari, David E., Vic Hasselblad, James E. Tcheng, Gregg W. Stone, Robert M. Califf, Adnan Kastrati, Franz-Josef Neumann, et al. “Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.” Am Heart J 147, no. 3 (March 2004): 457–62. https://doi.org/10.1016/j.ahj.2003.08.011.
       Full Text  Link to Item
    • Halkin, Amir, Eve Aymong, David A. Cox, Roxana Mehran, Alexandra J. Lansky, Martin Fahy, Giora Weisz, et al. “Relation between late patency of the infarct-related artery, left ventricular function, and clinical outcomes after primary percutaneous intervention for acute myocardial infarction (CADILLAC trial).” Am J Cardiol 93, no. 3 (February 1, 2004): 349–53. https://doi.org/10.1016/j.amjcard.2003.10.019.
       Full Text  Link to Item
    • Antoniucci, D., A. Rodriguez, A. Hempel, and J. E. Tcheng. “Trial finds adding abciximab to stent reperfusion improves survival in acute myocardial infarction.” Evidence Based Cardiovascular Medicine 8, no. 2 (January 1, 2004): 147–48. https://doi.org/10.1016/j.ebcm.2004.03.018.
       Full Text
    • Dery, J. P., R. A. Harrington, and J. E. Tcheng. “GP IIb/IIIa blockade in elective percutaneous coronary intervention.” Curr Pharm Des 10, no. 4 (2004): 387–98. https://doi.org/10.2174/1381612043453306.
       Full Text  Link to Item
    • Bakhai, Ameet, Gregg W. Stone, Cindy L. Grines, Sabina A. Murphy, Louise Githiora, Ronna H. Berezin, David A. Cox, et al. “Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial.” Circulation 108, no. 23 (December 9, 2003): 2857–63. https://doi.org/10.1161/01.CIR.0000103121.26241.FA.
       Full Text  Link to Item
    • Sadeghi, H Mehrdad, Gregg W. Stone, Cindy L. Grines, Roxana Mehran, Simon R. Dixon, Alexandra J. Lansky, Martin Fahy, et al. “Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction.” Circulation 108, no. 22 (December 2, 2003): 2769–75. https://doi.org/10.1161/01.CIR.0000103623.63687.21.
       Full Text  Link to Item
    • Ashby, Dale T., Eve A. Aymong, Cindy L. Grines, David A. Cox, Eulogio Garcia, Roxana Mehran, James E. Tcheng, et al. “Outcomes of bail-out stenting for suboptimal balloon angioplasty during primary intervention in acute myocardial infarction (The CADILLAC trial).” Am J Cardiol 92, no. 9 (November 1, 2003): 1095–98. https://doi.org/10.1016/j.amjcard.2003.06.006.
       Full Text  Link to Item
    • Ashby, Dale T., Eve A. Aymong, James E. Tcheng, Cindy L. Grines, David A. Cox, Roxana Mehran, Eulogio Garcia, et al. “Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial).” Am J Cardiol 92, no. 9 (November 1, 2003): 1091–94. https://doi.org/10.1016/j.amjcard.2003.06.005.
       Full Text  Link to Item
    • Gurm, H. S., D. L. Bhatt, A. M. Lincoff, J. E. Tcheng, D. J. Kereiakes, N. S. Kleiman, G. Jia, and E. J. Topol. “Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials.” Heart 89, no. 10 (October 2003): 1200–1204. https://doi.org/10.1136/heart.89.10.1200.
       Full Text  Link to Item
    • Kandzari, David E., James E. Tcheng, David J. Cohen, Ameet Bakhai, Cindy L. Grines, David A. Cox, Mark Effron, et al. “Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial).” Am J Cardiol 92, no. 7 (October 1, 2003): 779–84. https://doi.org/10.1016/s0002-9149(03)00882-8.
       Full Text  Link to Item
    • Tcheng, James E., and Mark E. Campbell. “Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition?” J Am Coll Cardiol 42, no. 7 (October 1, 2003): 1196–98. https://doi.org/10.1016/s0735-1097(03)00945-8.
       Full Text  Link to Item
    • Cox, David A., Gregg W. Stone, Cindy L. Grines, Thomas Stuckey, David J. Cohen, James E. Tcheng, Eulogio Garcia, et al. “Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial.” J Am Coll Cardiol 42, no. 6 (September 17, 2003): 971–77. https://doi.org/10.1016/s0735-1097(03)00911-2.
       Full Text  Link to Item
    • Moliterno, David J., James B. Hermiller, Dean J. Kereiakes, Eric Yow, Robert J. Applegate, Gregory A. Braden, Eric J. Dippel, et al. “A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study.” J Am Coll Cardiol 42, no. 6 (September 17, 2003): 1132–39. https://doi.org/10.1016/s0735-1097(03)01053-2.
       Full Text  Link to Item
    • Tcheng, James E., David E. Kandzari, Cindy L. Grines, David A. Cox, Mark B. Effron, Eulogio Garcia, John J. Griffin, et al. “Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.” Circulation 108, no. 11 (September 16, 2003): 1316–23. https://doi.org/10.1161/01.CIR.0000087601.45803.86.
       Full Text  Link to Item
    • Kandzari, David E., Marino Labinaz, Warren J. Cantor, Mina Madan, Dianne S. Gallup, Vic Hasselblad, Diane Joseph, et al. “Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial).” Am J Cardiol 92, no. 6 (September 15, 2003): 660–64. https://doi.org/10.1016/s0002-9149(03)00818-x.
       Full Text  Link to Item
    • Kong, David F., Vic Hasselblad, Robert A. Harrington, Harvey D. White, James E. Tcheng, David E. Kandzari, Eric J. Topol, and Robert M. Califf. “Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions.” Am J Cardiol 92, no. 6 (September 15, 2003): 651–55. https://doi.org/10.1016/s0002-9149(03)00816-6.
       Full Text  Link to Item
    • Kereiakes, Dean J., James Tcheng, Edward T. A. Fry, Deepak L. Bhatt, Gideon Bosker, Jose G. Diez, James J. Ferguson, et al. “Pharmacoinvasive management of acute coronary syndrome in the setting of percutaneous coronary intervention: evidence-based, site- and spectrum-of-care strategies for optimizing patient outcomes in NSTE-ACS.” J Invasive Cardiol 15, no. 9 (September 2003): 536–53.
       Link to Item
    • Ellis, Keith, James E. Tcheng, Shelly Sapp, Eric J. Topol, and A Michael Lincoff. “Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport Trials.” J Interv Cardiol 16, no. 4 (August 2003): 299–305. https://doi.org/10.1034/j.1600-6143.2003.08062.x.
       Full Text  Link to Item
    • Shimpi, Rahul A. “Low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors with percutaneous coronary intervention in acute coronary syndromes.” J Invasive Cardiol 15, no. 8 (August 2003): 460–65.
       Link to Item
    • Tcheng, James E., Mina Madan, J Conor O’Shea, Eric A. Cohen, Christopher E. Buller, A Michael Lincoff, Jeffrey J. Popma, et al. “Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention.” J Interv Cardiol 16, no. 2 (April 2003): 97–105. https://doi.org/10.1046/j.1540-8183.2003.08020.x.
       Full Text  Link to Item
    • Cannon, Christopher. “Improving acute coronary syndrome care: the ACC/AHA guidelines and critical pathways.” J Invasive Cardiol 15 Suppl B (March 2003): 22B-27B.
       Link to Item
    • Riesmeyer, Jeffrey S., Philip R. Reid, and Debra L. Miller. “Comparison of one-year outcomes...ESPRIT. Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy.” Am J Cardiol 91, no. 4 (February 15, 2003): 514–15. https://doi.org/10.1016/s0002-9149(02)03291-5.
       Full Text  Link to Item
    • Tolleson, Thaddeus R., J Conor O’Shea, John A. Bittl, William B. Hillegass, Kathryn A. Williams, Glenn Levine, Robert A. Harrington, and James E. Tcheng. “Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial.” J Am Coll Cardiol 41, no. 3 (February 5, 2003): 386–93. https://doi.org/10.1016/s0735-1097(02)02767-5.
       Full Text  Link to Item
    • Labinaz, Marino, James E. Tcheng, Karen Pieper, Gail Hafley, and Conor O’Shea. “Reply.” The American Journal of Cardiology 91, no. 4 (February 2003): 515–515. https://doi.org/10.1016/s0002-9149(02)03292-7.
       Full Text
    • Denardo, S. J., K. E. Davis, P. R. Reid, and J. E. Tcheng. “Efficacy and safety of minimal dose (.” The American Journal of Cardiology 91, no. 1 (January 2003): 1–5.
    • Denardo, Scott J., Keith E. Davis, Philip R. Reid, and James E. Tcheng. “Efficacy and safety of minimal dose (< or =1,000 units) unfractionated heparin with abciximab in percutaneous coronary intervention.” Am J Cardiol 91, no. 1 (January 1, 2003): 1–5. https://doi.org/10.1016/s0002-9149(02)02988-0.
       Full Text  Link to Item
    • Kandzari, David E., and James E. Tcheng. “Double negatives.” Am Heart J 145, no. 1 (January 2003): 9–11. https://doi.org/10.1067/mhj.2003.33.
       Full Text  Link to Item
    • Reddan, Donal N., John Conor O’Shea, Ian J. Sarembock, Kathryn A. Williams, Karen S. Pieper, Edward Santoian, William F. Owen, Michael M. Kitt, and James E. Tcheng. “Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial).” Am J Cardiol 91, no. 1 (January 1, 2003): 17–21. https://doi.org/10.1016/s0002-9149(02)02991-0.
       Full Text  Link to Item
    • Wagner, C. L., A. Schantz, E. Barnathan, A. Olson, M. A. Mascelli, J. Ford, L. Damaraju, T. Schaible, R. N. Maini, and J. E. Tcheng. “Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade.” Dev Biol (Basel) 112 (2003): 37–53.
       Link to Item
    • Toffaletti, J. G., E. H. McDonnell, I. Welsby, I. R. Shearer, M. H. Sketch, and J. E. Tcheng. “Implementing a New Method for Activated Clotting Time.” Plastic Surgical Nursing 2, no. 2 (January 1, 2003): 125–28. https://doi.org/10.1097/00134384-200306000-00009.
       Full Text
    • Blankenship, James C., Craig Balog, Shelly K. Sapp, Robert M. Califf, A Michael Lincoff, James E. Tcheng, and Eric J. Topol. “Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials.” Catheter Cardiovasc Interv 57, no. 4 (December 2002): 476–83. https://doi.org/10.1002/ccd.10322.
       Full Text  Link to Item
    • Shah, Svati H., Michael H. Sketch, and James E. Tcheng. “Acute myocardial infarction in a young male while playing paintball.” J Invasive Cardiol 14, no. 11 (November 2002): 713–15.
       Link to Item
    • Islam, M Ashequl, James C. Blankenship, Craig Balog, Elias A. Iliadis, A Michael Lincoff, James E. Tcheng, Robert M. Califf, Eric J. Topol, and Eric J. EPISTENT Investigators. “Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT).” Am J Cardiol 90, no. 9 (November 1, 2002): 916–21. https://doi.org/10.1016/s0002-9149(02)02653-x.
       Full Text  Link to Item
    • Dery, J. P., J. C. O’Shea, and J. E. Tcheng. “Eptifibatide in percutaneous coronary intervention. A review.” Minerva Cardioangiol 50, no. 5 (October 2002): 531–46.
       Link to Item
    • Fernandes, Laura S., James E. Tcheng, J Conor O’Shea, Bonnie Weiner, Todd J. Lorenz, Cindy Pacchiana, Lisa G. Berdan, et al. “Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study.” J Am Coll Cardiol 40, no. 6 (September 18, 2002): 1085–91. https://doi.org/10.1016/s0735-1097(02)02120-4.
       Full Text  Link to Item
    • Batchelor, Wayne B., Thaddeus R. Tolleson, Yao Huang, Rhonda L. Larsen, R Michael Mantell, Patricia Dillard, Marie Davidian, et al. “Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.” Circulation 106, no. 12 (September 17, 2002): 1470–76. https://doi.org/10.1161/01.cir.0000029744.01096.1f.
       Full Text  Link to Item
    • Labinaz, Marino, Mina Madan, J O’Conor O’Shea, Rakhi Kilaru, Wai Chin, Karen Pieper, Darren K. McGuire, et al. “Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial).” Am J Cardiol 90, no. 6 (September 15, 2002): 585–90. https://doi.org/10.1016/s0002-9149(02)02560-2.
       Full Text  Link to Item
    • Holmes, David R., Michael Savage, J. -. M. LaBlanche, Lars Grip, P. W. Serruys, Peter Fitzgerald, David Fischman, et al. “Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial.” Circulation 106, no. 10 (September 3, 2002): 1243–50. https://doi.org/10.1161/01.cir.0000028335.31300.da.
       Full Text  Link to Item
    • Hillegass, William B., Brigitta C. Brott, Gregory D. Chapman, Harry R. Phillips, Richard S. Stack, James E. Tcheng, and Robert M. Califf. “Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications.” Am Heart J 144, no. 3 (September 2002): 501–7. https://doi.org/10.1067/mhj.2002.123143.
       Full Text  Link to Item
    • Herrmann, Howard C. “Comparison of angioplasty with stenting in acute myocardial infarction.” N Engl J Med 347, no. 5 (August 1, 2002): 367–68. https://doi.org/10.1056/NEJM200208013470515.
       Full Text  Link to Item
    • Kandzari, David E., James E. Tcheng, and James P. Zidar. “Coronary artery stents: evaluating new designs for contemporary percutaneous intervention.” Catheter Cardiovasc Interv 56, no. 4 (August 2002): 562–76. https://doi.org/10.1002/ccd.10248.
       Full Text  Link to Item
    • O’Shea, J Conor, and James E. Tcheng. “Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa.” Expert Opin Pharmacother 3, no. 8 (August 2002): 1199–1210. https://doi.org/10.1517/14656566.3.8.1199.
       Full Text  Link to Item
    • Gurm, Hitinder S., Danielle M. Brennan, Joan Booth, James E. Tcheng, A Michael Lincoff, and Eric J. Topol. “Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox).” Am J Cardiol 90, no. 1 (July 1, 2002): 42–45. https://doi.org/10.1016/s0002-9149(02)02384-6.
       Full Text  Link to Item
    • Madan, Mina, Scott D. Berkowitz, Douglas J. Christie, Astrid C. Smit, Kristina N. Sigmon, and James E. Tcheng. “Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100.” Am Heart J 144, no. 1 (July 2002): 151–58. https://doi.org/10.1067/mhj.2002.123581.
       Full Text  Link to Item
    • Topol, Eric J., A Michael Lincoff, Dean J. Kereiakes, Neal S. Kleiman, Eric A. Cohen, James J. Ferguson, James E. Tcheng, Shelly Sapp, and Robert M. Califf. “Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization.” Am J Med 113, no. 1 (July 2002): 1–6. https://doi.org/10.1016/s0002-9343(02)01145-2.
       Full Text  Link to Item
    • Stone, Gregg W., Cindy L. Grines, David A. Cox, Eulogio Garcia, James E. Tcheng, John J. Griffin, Giulio Guagliumi, et al. “Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.” N Engl J Med 346, no. 13 (March 28, 2002): 957–66. https://doi.org/10.1056/NEJMoa013404.
       Full Text  Link to Item
    • Dyke, C. K., D. K. Benjamin, C. L. Nelson, K. Newby, C. O’shea, W. Cantor, C. Nguyen, J. H. Alexander, M. M. Kitt, and J. E. Tcheng. “Elevated troponin following percutaneous coronary intervention predicts subsequent events: Results from the ESPRIT trial.” Journal of the American College of Cardiology 39, no. 5 (March 6, 2002): 72A-72A.
       Link to Item
    • Steinhubl, S. R., J. F. Saucedo, D. C. Sane, P. B. Berger, D. J. Moliterno, J. E. Tcheng, and D. J. Kereiakes. “Point-of-care measurement of platelet function before angioplasty strongly predicts future target vessel revascularization.” Journal of the American College of Cardiology 39, no. 5 (March 6, 2002): 72A-72A.
       Link to Item
    • Sharayeva, Marina L., James E. Tcheng, and Christopher P. Cannon. “Assessment of compliance with the American College of Cardiology/American Heart Association guidelines for patients with acute coronary syndromes admitted to a tertiary care hospital coronary care unit.” Crit Pathw Cardiol 1, no. 1 (March 2002): 22–25. https://doi.org/10.1097/00132577-200203000-00005.
       Full Text  Link to Item
    • O’Shea, J Conor, Christopher E. Buller, Warren J. Cantor, A Bleakley Chandler, Eric A. Cohen, David J. Cohen, Ian C. Gilchrist, et al. “Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention.” Jama 287, no. 5 (February 6, 2002): 618–21. https://doi.org/10.1001/jama.287.5.618.
       Full Text  Link to Item
    • Cohen, David J., J Conor O’Shea, Cindy M. Pacchiana, Glenn Levine, Ian Sarembock, James Slater, Eric Conn, Jack Smith, James E. Tcheng, and James E. ESPRIT investigators. “In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin.” Am J Cardiol 89, no. 1 (January 1, 2002): 61–64. https://doi.org/10.1016/s0002-9149(01)02165-8.
       Full Text  Link to Item
    • Gibson, C Michael, Sabina A. Murphy, Susan J. Marble, David J. Cohen, Eric A. Cohen, Henry K. Lui, Jeffrey Young, Michael M. Kitt, Todd J. Lorenz, and James E. Tcheng. “Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy.” Am Heart J 143, no. 1 (January 2002): 106–10. https://doi.org/10.1067/mhj.2002.119618.
       Full Text  Link to Item
    • Tcheng, J. E., J. D. Talley, J. C. O’Shea, I. C. Gilchrist, N. S. Kleiman, C. L. Grines, C. J. Davidson, et al. “Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study).” Am J Cardiol 88, no. 10 (November 15, 2001): 1097–1102. https://doi.org/10.1016/s0002-9149(01)02041-0.
       Full Text  Link to Item
    • Blankenship, J. C., K. N. Sigmon, K. S. Pieper, C. O’Shea, B. E. Tardiff, J. E. Tcheng, and J. E. IMPACT-II Investigators. “Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT--(Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II Trial.” Am J Cardiol 88, no. 9 (November 1, 2001): 969–73. https://doi.org/10.1016/s0002-9149(01)01972-5.
       Full Text  Link to Item
    • Tcheng, J. E., J. Strony, T. J. Lorenz, and J. C. O’Shea. “ESPRIT in context: pharmacology matters!.” Eur Heart J 22, no. 21 (November 2001): 1965–67. https://doi.org/10.1053/euhj.2001.2682.
       Full Text  Link to Item
    • Cohen, D. J., R. S. Cosgrove, R. H. Berezin, J. O’Shea, M. M. Kitt, I. Gilchrist, D. B. Mark, and J. E. Tcheng. “Cost-effectiveness of eptifibatide in patients undergoing planned coronary stenting: Results from the ESPRIT trial.” Circulation 104, no. 17 (October 23, 2001): 386–87.
       Link to Item
    • Quinn, M. J., A. M. M. Lincoff, D. J. Kereiakes, N. S. Kleiman, E. A. Cohen, J. J. Ferguson, J. E. Tcheng, R. M. Califf, and E. J. Topol. “Long-term mortality benefit of abciximab in percutaneous intervention.” Circulation 104, no. 17 (October 23, 2001): 387–387.
       Link to Item
    • Rebeiz, A. G., K. S. Pieper, J. C. O’Shea, I. C. Gilchrist, B. Chandler, J. Slater, J. B. Muhlestein, et al. “16 to 18-hour infusions of eptifibatide seem optimal in reducing ischemic complications following percutaneous coronary intervention.” Circulation 104, no. 17 (October 23, 2001): 386–386.
       Link to Item
    • Tcheng, J. E., E. A. Cohen, C. E. Buller, D. J. Cohen, M. Madan, M. M. Kitt, W. J. Cantor, et al. “Eptifibatide (Integrilin (R)) in coronary stent implantation: Long-term results of the ESPRIT trial.” Circulation 104, no. 17 (October 23, 2001): 94–94.
       Link to Item
    • Carcia, E., D. A. Cox, C. L. Grines, T. Stuckey, J. E. Tcheng, B. D. Rutherford, J. McLean, J. Carroll, A. J. Lansky, and G. W. Stone. “Does primary stenting benefit proximal LAD infarction? The CADILLAC trial.” American Journal of Cardiology 88, no. 5A (September 11, 2001): 64G-64G.
       Link to Item
    • Cox, D. A., C. L. Grines, E. Garcia, T. Stuckey, J. E. Tcheng, G. Guagliumi, A. Johnson, J. Griffin, A. Lansky, and G. W. Stone. “Does "Optimal" percutaneous transluminal coronary angioplasty (PTCA) provide equivalent outcomes in acute myocardial infarction (AMI) compared with stenting? Insights from the CADILLAC trial.” American Journal of Cardiology 88, no. 5A (September 11, 2001): 27G-27G.
       Link to Item
    • Guagliumi, G., D. A. Cox, C. L. Grines, E. Garcia, T. Stuckey, J. E. Tcheng, J. Pasquini, J. Carroll, A. J. Lansky, and G. W. Stone. “Outcomes in elderly patients undergoing primary coronary intervention for AMI: Insights from the CADILLAC trial.” American Journal of Cardiology 88, no. 5A (September 11, 2001): 64G-65G.
       Link to Item
    • Blankenship, J. C., G. Tasissa, J. C. O’Shea, E. A. Iliadis, F. A. Bachour, D. J. Cohen, H. K. Lui, et al. “Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial.” J Am Coll Cardiol 38, no. 3 (September 2001): 653–58. https://doi.org/10.1016/s0735-1097(01)01423-1.
       Full Text  Link to Item
    • Gurm, H., J. E. Tcheng, A. M. Lincoff, and D. Prosper. “Body mass index remains a significant predictor of outcome after percutaneous coronary interventions in the era of IIbIIIa inhibition.” European Heart Journal 22 (September 1, 2001): 524–524.
       Link to Item
    • O’Shea, J. C., E. A. Cohen, C. E. Buller, G. Hafley, M. M. Kitt, T. J. Lorenz, R. M. Califf, J. E. Tcheng, M. Madan, and D. J. Cohen. “Eptifibatide (Integrilin (R)) in coronary stent implantation: long-term results of the ESPRIT trial.” European Heart Journal 22 (September 1, 2001): 121–121.
       Link to Item
    • Tcheng, J. E., D. J. Kereiakes, A. M. Lincoff, B. S. George, N. S. Kleiman, D. C. Sane, D. B. Cines, et al. “Abciximab readministration: results of the ReoPro Readministration Registry.” Circulation 104, no. 8 (August 21, 2001): 870–75. https://doi.org/10.1161/hc3301.094533.
       Full Text  Link to Item
    • Gilchrist, I. C., J. C. O’Shea, T. Kosoglou, L. K. Jennings, T. J. Lorenz, M. M. Kitt, N. S. Kleiman, et al. “Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention.” Circulation 104, no. 4 (July 24, 2001): 406–11. https://doi.org/10.1161/hc2901.093504.
       Full Text  Link to Item
    • Akkerhuis, K. M., J. W. Deckers, A. M. Lincoff, J. E. Tcheng, E. Boersma, K. Anderson, C. Balog, R. M. Califf, E. J. Topol, and M. L. Simoons. “Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention.” Jama 286, no. 1 (July 4, 2001): 78–82. https://doi.org/10.1001/jama.286.1.78.
       Full Text  Link to Item
    • Gehrig, T. R., M. H. Sketch, and J. E. Tcheng. “No jacket required.” J Invasive Cardiol 13, no. 7 (July 2001): 516–18.
       Link to Item
    • Gibson, C. M., D. J. Cohen, E. A. Cohen, H. K. Lui, S. A. Murphy, S. J. Marble, M. Kitt, T. Lorenz, and J. E. Tcheng. “Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy.” Am J Cardiol 87, no. 11 (June 1, 2001): 1293–95. https://doi.org/10.1016/s0002-9149(01)01524-7.
       Full Text  Link to Item
    • Cantor, W. J., A. S. Hellkamp, E. D. Peterson, J. P. Zidar, P. A. Cowper, M. H. Sketch, J. E. Tcheng, R. M. Califf, and E. M. Ohman. “Achieving optimal results with standard balloon angioplasty: can baseline and angiographic variables predict stent-like outcomes?” J Am Coll Cardiol 37, no. 7 (June 1, 2001): 1883–90. https://doi.org/10.1016/s0735-1097(01)01244-x.
       Full Text  Link to Item
    • Steinhubl, S. R., J. D. Talley, G. A. Braden, J. E. Tcheng, P. J. Casterella, D. J. Moliterno, F. I. Navetta, et al. “Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.” Circulation 103, no. 21 (May 29, 2001): 2572–78. https://doi.org/10.1161/01.cir.103.21.2572.
       Full Text  Link to Item
    • O’Shea, J. C., G. E. Hafley, S. Greenberg, V. Hasselblad, T. J. Lorenz, M. M. Kitt, J. Strony, J. E. Tcheng, and J. E. ESPRIT Investigators (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy trial). “Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial.” Jama 285, no. 19 (May 16, 2001): 2468–73. https://doi.org/10.1001/jama.285.19.2468.
       Full Text  Link to Item
    • Brown, D. L. “Drug-company sponsorship and the Declaration of Helsinki.” Lancet 357, no. 9266 (May 5, 2001): 1448–49. https://doi.org/10.1016/S0140-6736(00)04603-1.
       Full Text  Link to Item
    • O’Shea, J Conor, and James E. Tcheng. “Drug-company sponsorship and the Declaration of Helsinki.” The Lancet 357, no. 9266 (May 2001): 1448–49. https://doi.org/10.1016/s0140-6736(00)04604-3.
       Full Text
    • Bachour, F. A., J. C. Blankenship, E. A. Iliadis, G. Tasissa, J. C. O’Shea, M. M. Kitt, T. J. Lorenz, and J. E. Tcheng. “Effect of glycoprotein IIb/IIIa receptor inhibition on in-lab adverse events and subsequent CK-MB elevation during percutaneous coronary intervention in ESPRIT.” Journal of the American College of Cardiology 37, no. 2 (February 1, 2001): 84A-84A.
       Link to Item
    • Cantor, W. J., A. S. Hellkamp, J. C. O’Shea, M. Madan, R. J. Chisholm, T. J. Lorenz, M. M. Kitt, et al. “Bailout platelet GP IIb/IIIa inhibition in coronary stent implantation: Observations from the ESPRIT trial.” Journal of the American College of Cardiology 37, no. 2 (February 1, 2001): 84A-84A.
       Link to Item
    • Chandler, B., J. C. O’Shea, S. Greenberg, J. Slater, J. M. Kirshenbaum, J. B. Muhlestein, C. M. Pacchiana, et al. “Robust benefit of platelet GP IIb-IIIa inhibition with eptifibatide in patients undergoing stent PCI with hot or cold presentation.” Journal of the American College of Cardiology 37, no. 2 (February 1, 2001): 76A-77A.
       Link to Item
    • Cohen, E. A., M. Lincoff, S. Sapp, J. R. Burton, J. E. Tcheng, and E. Topol. “Variations in event rates between Canada and United States in the EPISTENT trial.” Journal of the American College of Cardiology 37, no. 2 (February 1, 2001): 81A-81A.
       Link to Item
    • Grines, C. L., D. A. Cox, J. E. Tcheng, E. Garcia, T. Stuckey, J. Carroll, G. Guagliumi, et al. “Effect of stent implantation and glycoprotein IIb/IIIa receptor blockade on TIMI flow and mortality after primary PTCA in acute myocardial infarction: Final results of the CADILLAC Trial.” Journal of the American College of Cardiology 37, no. 2 (February 1, 2001): 342S-342S.
       Link to Item
    • Madan, M., S. D. Berkowitz, D. J. Christie, L. K. Jennings, A. C. Smit, K. N. Sigmon, S. Glazer, and J. E. Tcheng. “Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention.” Am Heart J 141, no. 2 (February 2001): 226–33. https://doi.org/10.1067/mhj.2001.112489.
       Full Text  Link to Item
    • O’Shea, J Conor, and James E. Tcheng. “Eptifibatide in Percutaneous Coronary Intervention: The ESPRIT Trial Results.” Curr Interv Cardiol Rep 3, no. 1 (February 2001): 62–68.
       Link to Item
    • O’Shea, J. C., T. Mann, A. Hellkamp, E. Cohen, R. Chisholm, W. J. Cantor, I. Gilchrist, et al. “Fewer bleeding complications with comparable efficacy with the transradial approach in coronary artery stenting: An analysis of the ESPRIT trial.” Journal of the American College of Cardiology 37, no. 2 (February 1, 2001): 33A-33A.
       Link to Item
    • Reddan, D. N., J. C. O’Shea, K. Williams, T. Lorenz, M. Kitt, E. Santoian, G. Levine, L. Sarembock, W. F. Owen, and J. E. Tcheng. “Treatment effect at different levels of creatinine clearance following eptifibatide in planned coronary stent implantation.” Journal of the American College of Cardiology 37, no. 2 (February 1, 2001): 11A-11A.
       Link to Item
    • Stone, G. W., C. L. Grines, D. A. Cox, E. Garcia, J. E. Tcheng, T. Stuckey, J. Carroll, et al. “A prospective, multicenter, international randomized trial comparing four reperfusion strategies in acute myocardial infarction: Principal report of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.” Journal of the American College of Cardiology 37, no. 2 (February 1, 2001): 342S-342S.
       Link to Item
    • Stuckey, T., C. L. Grines, D. A. Cox, E. Garcia, J. E. Tcheng, J. Carroll, B. Rutherford, et al. “Does stenting and glycoprotein IIb/IIIa receptor blockade improve the prognosis of diabetics undergoing primary angioplasty in acute myocardial infarction? The CADILLAC trial.” Journal of the American College of Cardiology 37, no. 2 (February 1, 2001): 342S-342S.
       Link to Item
    • Tcheng, J. E., J. C. O’Shea, E. A. Cohen, C. E. Buller, A. M. Lincoff, D. Joseph, P. S. Teirstein, et al. “High-dose eptifibatide (Integrilin (R)) in coronary stent implantation: 1 year results of the ESPRIT trial.” Journal of the American College of Cardiology 37, no. 2 (February 1, 2001): 76A-76A.
       Link to Item
    • Tcheng, J. E., M. Effron, C. L. Grines, E. Garcia, D. Cox, T. Stuckey, J. Carroll, et al. “Abciximab use during percutaneous intervention in patients with acute myocardial infarction improves early and late clinical outcomes: Final results of the CADILLAC trial.” Journal of the American College of Cardiology 37, no. 2 (February 1, 2001): 343A-343A.
       Link to Item
    • Tcheng, J. E., and A. A. Volkert-Noethen. “Current multicentre studies with the excimer laser: design and aims.” Lasers Med Sci 16, no. 2 (2001): 122–29. https://doi.org/10.1007/pl00011341.
       Full Text  Link to Item
    • ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy, Christoph. “Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.” Lancet 356, no. 9247 (December 16, 2000): 2037–44. https://doi.org/10.1016/S0140-6736(00)03400-0.
       Full Text  Link to Item
    • Lincoff, A. M., D. B. Mark, J. E. Tcheng, R. M. Califf, M. V. Bala, K. M. Anderson, L. Davidson-Ray, J. D. Knight, C. F. Cabot, and E. J. Topol. “Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.” Circulation 102, no. 24 (December 12, 2000): 2923–29. https://doi.org/10.1161/01.cir.102.24.2923.
       Full Text  Link to Item
    • O’Shea, J. C., and J. E. Tcheng. “Small-molecule glycoprotein IIb/IIIa inhibitors as adjunctive therapy in percutaneous coronary interventions.” J Thromb Thrombolysis 10, no. 3 (December 2000): 211–15. https://doi.org/10.1023/a:1026530804807.
       Full Text  Link to Item
    • O’shea, J. C., M. Madan, W. J. Cantor, C. M. Pacchiana, S. Greenberg, D. M. Joseph, M. M. Kitt, T. J. Lorenz, and J. E. Tcheng. “Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention.” Am Heart J 140, no. 6 (December 2000): 834–39. https://doi.org/10.1067/mhj.2000.110458.
       Full Text  Link to Item
    • Burris, N., R. A. Lippincott, A. Elfe, J. E. Tcheng, J. C. O’Shea, and C. Reiser. “Effects of 308 nanometer excimer laser energy on 316 L stainless-steel stents: implications for laser atherectomy of in-stent restenosis.” J Invasive Cardiol 12, no. 11 (November 2000): 555–59.
       Link to Item
    • Denardo, S. J., K. E. Davis, J. E. Tcheng, and P. R. Reid. “Extremely low dose heparin with abciximab in coronary intervention: Improved efficacy and decreased bleeding complications using a novel heparin dosing strategy.” Circulation 102, no. 18 (October 31, 2000): 785–785.
       Link to Item
    • Fernandes, L. S., J. E. Tcheng, N. S. Kleiman, B. H. Weiner, T. J. Lorenz, C. Pacchiana, J. C. O’Shea, et al. “Eptifibatide is as effective in women as in men: Lessons from the ESPRIT trial.” Circulation 102, no. 18 (October 31, 2000): 785–785.
       Link to Item
    • Gibson, C. M., D. J. Cohen, E. A. Cohen, H. Lui, L. Luu, C. Hynes, T. Saunders, et al. “Eptifibatide improves coronary flow reserve following stent placement: An ESPRIT substudy.” Circulation 102, no. 18 (October 31, 2000): 366–366.
       Link to Item
    • Gilchrist, I. C., C. M. Pacchiana, W. J. Cantor, J. C. Blankenship, P. Seidelin, J. Ducas, W. Sheldon, et al. “Temporal spectrum of ischemic complications with percutaneous coronary intervention: The ESPRIT experience.” Circulation 102, no. 18 (October 31, 2000): 640–640.
       Link to Item
    • Labinaz, M., M. Madan, D. K. McGuire, W. Batchelor, J. Saucedo, C. Pacchiana, M. M. Kitt, et al. “Effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, among diabetic patients following coronary stenting: Results from ESPRIT.” Circulation 102, no. 18 (October 31, 2000): 665-+.
       Link to Item
    • Steinhubl, S. R., J. D. Talley, D. J. Kereiakes, G. A. Braden, J. E. Tcheng, P. J. Casterella, D. J. Moliterno, et al. “Correlates of baseline platelet function as measured by the Ultegra-RPFA and its asssociation with the level of platelet inhibition achieved with GPIIb/IIIa inhibitor therapy. Results from the GOLD study.” Circulation 102, no. 18 (October 31, 2000): 418–19.
       Link to Item
    • Stone, G. W., C. L. Grines, D. A. Cox, T. Stuckey, J. D. Carroll, G. Guagliumi, B. D. Rutherford, et al. “A prospective, randomized trial comparing primary balloon angioplasty with or without abciximab to primary stenting with or without abciximab in acute myocardial infarction - Primary endpoint analysis from the CADILLAC Trial.” Circulation 102, no. 18 (October 31, 2000): 664-+.
       Link to Item
    • Tcheng, J. E., E. A. Cohen, C. E. H. Buller, A. M. Lincoff, D. Joseph, P. S. Teirstein, C. M. Pacchiana, et al. “High-dose eptifibatide (Integrilln (R)) in coronary stent implantation: 6 month results of the ESPRIT trial.” Circulation 102, no. 18 (October 31, 2000): 663–663.
       Link to Item
    • Tolleson, T. R., J. Bittl, J. C. O’Shea, J. Saucedo, G. Levine, M. Lopez, M. M. Kitt, et al. “Relationship between maximum procedural act and safety/efficacy in ESPRIT/IMPACT II.” Circulation 102, no. 18 (October 31, 2000): 665–665.
       Link to Item
    • Wightman, M. B., V. Bindal, P. A. Cowper, L. H. Muhlbaier, R. Warwrzynski, J. E. Tcheng, M. H. Sketch, T. Ryan, and E. D. Peterson. “Limitations in the APRDRG as a measure of severity.” Circulation 102, no. 18 (October 31, 2000): 877–877.
       Link to Item
    • O’Shea, J. C., T. J. Lorenz, D. Joseph, M. M. Kitt, S. Greenberg, H. Lui, W. Cantor, E. Cohen, and J. E. Tcheng. “Robust benefit of glycoprotein IIb/IIIa inhibition with eptifibatide in patients undergoing stent percutaneous coronary intervention with positive cardiac markers at baseline.” American Journal of Cardiology 86, no. 8A (October 16, 2000): 13I-14I.
       Link to Item
    • Cantor, W. J., E. D. Peterson, J. J. Popma, J. P. Zidar, M. H. Sketch, J. E. Tcheng, and E. M. Ohman. “Provisional stenting strategies: systematic overview and implications for clinical decision-making.” J Am Coll Cardiol 36, no. 4 (October 2000): 1142–51. https://doi.org/10.1016/s0735-1097(00)00854-8.
       Full Text  Link to Item
    • Kandzari, D. E., J. E. Tcheng, R. A. Harrington, and M. H. Sketch. “"Rescue" platelet GP IIb/IIIa inhibitor therapy in percutaneous coronary intervention: bailing out of a sunken ship.” J Invasive Cardiol 12, no. 10 (October 2000): 502–4.
       Link to Item
    • Madan, M., and J. E. Tcheng. “Update on Abciximab Readministration During Percutaneous Coronary Interventions.” Curr Interv Cardiol Rep 2, no. 3 (August 2000): 244–49.
       Link to Item
    • Steinhubl, S., D. Talley, D. J. Kereiakes, G. A. Braden, J. E. Tcheng, P. J. Casterella, D. J. Moliterno, P. B. Berger, and E. J. Topol. “The level of platelet inhibition maintained with a GPIIb/IIIa inhibitor following coronary intervention is strongly associated with the risk of a post-procedural MACE: results of the GOLD study.” European Heart Journal 21 (August 1, 2000): 145–145.
       Link to Item
    • Cho, L., E. J. Topol, C. Balog, J. M. Foody, J. E. Booth, C. Cabot, N. S. Kleiman, J. E. Tcheng, R. Califf, and A. M. Lincoff. “Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent.” J Am Coll Cardiol 36, no. 2 (August 2000): 381–86. https://doi.org/10.1016/s0735-1097(00)00746-4.
       Full Text  Link to Item
    • Lincoff, A. M., L. A. LeNarz, G. J. Despotis, P. K. Smith, J. E. Booth, R. E. Raymond, S. K. Sapp, et al. “Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing.” Ann Thorac Surg 70, no. 2 (August 2000): 516–26. https://doi.org/10.1016/s0003-4975(00)01343-6.
       Full Text  Link to Item
    • Liptay, M. J., G. A. Masters, D. J. Winchester, B. L. Edelman, B. J. Garrido, T. R. Hirschtritt, R. M. Perlman, and W. A. Fry. “Intraoperative radioisotope sentinel lymph node mapping in non-small cell lung cancer.” Ann Thorac Surg 70, no. 2 (August 2000): 384–89. https://doi.org/10.1016/s0003-4975(00)01643-x.
       Full Text  Link to Item
    • Tcheng, J. E. “High-dose eptifibatide in elective coronary stenting: Results of the ESPRIT trial.” Journal of the American College of Cardiology 36, no. 1 (July 1, 2000): 321–321.
       Link to Item
    • Kereiakes, D. J., S. D. Berkowitz, A. M. Lincoff, J. E. Tcheng, K. Wolski, R. Achenbach, R. Melsheimer, K. Anderson, R. M. Califf, and E. J. Topol. “Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade.” Am Heart J 140, no. 1 (July 2000): 74–80. https://doi.org/10.1067/mhj.2000.106615.
       Full Text  Link to Item
    • Bhatt, D. L., A. M. Lincoff, R. M. Califf, M. L. Simoons, J. E. Tcheng, S. J. Brener, K. E. Wolski, and E. J. Topol. “The benefit of abciximab in percutaneous coronary revascularization is not device-specific.” Am J Cardiol 85, no. 9 (May 1, 2000): 1060–64. https://doi.org/10.1016/s0002-9149(00)00696-2.
       Full Text  Link to Item
    • Tanguay, J. F., W. J. Cantor, M. W. Krucoff, B. Muhlestein, G. W. Barsness, J. P. Zidar, M. H. Sketch, et al. “Local delivery of heparin post-PTCA: a multicenter randomized pilot study.” Catheter Cardiovasc Interv 49, no. 4 (April 2000): 461–67. https://doi.org/10.1002/(sici)1522-726x(200004)49:4<461::aid-ccd26>3.0.co;2-7.
       Full Text  Link to Item
    • Cohen, M. G., D. F. Kong, J. J. Warner, M. B. Wightman, A. B. Greenbaum, J. E. Tcheng, R. H. Peter, M. H. Sketch, L. H. Muhlbaier, and J. P. Zidar. “Outcomes following interventions in small coronary arteries with the use of hand-crimped Palmaz-Schatz stents.” Am J Cardiol 85, no. 4 (February 15, 2000): 446–50. https://doi.org/10.1016/s0002-9149(99)00770-5.
       Full Text  Link to Item
    • Madan, M., D. J. Kereiakes, J. B. Hermiller, M. M. Rund, G. Tudor, L. Anderson, M. B. McDonald, et al. “Efficacy of abciximab readministration in coronary intervention.” Am J Cardiol 85, no. 4 (February 15, 2000): 435–40. https://doi.org/10.1016/s0002-9149(99)00768-7.
       Full Text  Link to Item
    • Thel, M. C., R. M. Califf, B. E. Tardiff, L. H. Gardner, K. N. Sigmon, A. M. Lincoff, E. J. Topol, M. M. Kitt, J. C. Blankenship, and J. E. Tcheng. “Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.” Am J Cardiol 85, no. 4 (February 15, 2000): 427–34. https://doi.org/10.1016/s0002-9149(99)00767-5.
       Full Text  Link to Item
    • Bhatt, D. L., A. M. Lincoff, J. E. Tcheng, R. M. Califf, P. L. L’Allier, S. P. Marso, K. E. Wolski, D. J. Kereiakes, and E. J. Topol. “The impact of abciximab on mortality after multivessel PCI: A striking effect in diabetics.” Journal of the American College of Cardiology 35, no. 2 (February 1, 2000): 91A-91A.
       Link to Item
    • Kereiakes, D. J., S. D. Berkowitz, A. M. Lincoff, J. E. Tcheng, K. Wolski, R. M. Califf, and E. J. Topol. “Abciximab thrombocytopenia: Clinical correlates and outcomes.” Journal of the American College of Cardiology 35, no. 2 (February 1, 2000): 91A-92A.
       Link to Item
    • Tcheng, J. E. “Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment.” Am Heart J 139, no. 2 Pt 2 (February 2000): S38–45. https://doi.org/10.1067/mhj.2000.103742.
       Full Text  Link to Item
    • Huay-Cheem, T. A. N., J. Crowley, J. E. Tcheng, S. N. G. Li-Wah, M. H. Sketch, H. R. Phillips, R. H. Peter, V. S. Behar, R. S. Stack, and J. P. Zidar. “Treatment of Palmaz-Schatz in-stent restenosis: 6-Month clinical follow-up.” Journal of Interventional Cardiology 13, no. 5 (January 1, 2000): 315–22. https://doi.org/10.1111/j.1540-8183.2000.tb00309.x.
       Full Text
    • Madan, M., and J. E. Tcheng. “Coronary intervention and glycoprotein IIb/IIIa integrin blockade.” Coron Artery Dis 10, no. 8 (December 1999): 553–60. https://doi.org/10.1097/00019501-199912000-00003.
       Full Text  Link to Item
    • Pracyk, J. B., S. Drennan, and J. E. Tcheng. “Hemostasis of the femoral vasculature: Shouldn't we have an answer by now?” Am Heart J 138, no. 6 Pt 1 (December 1999): 1014–15. https://doi.org/10.1016/s0002-8703(99)70063-3.
       Full Text  Link to Item
    • Marks, D. S., M. B. Effron, G. A. Mensah, S. E. Fitzpatrick, J. E. Tcheng, and D. F. Kereiakes. “Abciximab markedly reduces 30-day adverse outcomes in black patients undergoing coronary intervention.” Circulation 100, no. 18 (November 2, 1999): 104–104.
       Link to Item
    • Roe, M. T., P. A. Gum, J. E. Booth, G. Jia, L. Damaraju, S. E. Fitzpatrick, D. J. Kereiakes, and J. E. Tcheng. “Consistent and durable reduction in death and myocardial infarction with abciximab during coronary intervention in acute coronary syndromes and stable angina: A pooled analysis from EPIC, EPILOG, and EPISTENT.” Circulation 100, no. 18 (November 2, 1999): 187–187.
       Link to Item
    • Tcheng, J. E., and J. C. O’Shea. “Eptifibatide: a potent inhibitor of the platelet receptor integrin, glycoprotein IIb/IIIa.” Expert Opin Investig Drugs 8, no. 11 (November 1999): 1893–1905. https://doi.org/10.1517/13543784.8.11.1893.
       Full Text  Link to Item
    • Gilchrist, I. C., L. H. Gardner, J. B. Muhlestein, A. M. Arnold, A. M. Lincoff, R. M. Califf, J. E. Tcheng, and E. J. Topol. “Effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experience.” Am Heart J 138, no. 5 Pt 1 (November 1999): 976–82. https://doi.org/10.1016/s0002-8703(99)70026-8.
       Full Text  Link to Item
    • Tcheng, J. E. “A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes.” Am Heart J 138, no. 4 Pt 2 (October 1999): 261–62. https://doi.org/10.1053/hj.1999.v138.a100464.
       Full Text  Link to Item
    • Tcheng, J. E., and D. F. Kong. “Vale, warfarin: a stentorian farewell.” Am Heart J 138, no. 4 Pt 1 (October 1999): 602–5. https://doi.org/10.1016/s0002-8703(99)70169-9.
       Full Text  Link to Item
    • Anderson, K. M., C. F. Cabot, and J. E. Tcheng. “Abciximab reduces in-hospital events among patients undergoing percutaneous coronary intervention.” American Journal of Cardiology 84, no. 6A (September 22, 1999): 67P-67P.
       Link to Item
    • Cabot, C. F., K. M. Anderson, J. E. Tcheng, and A. M. Lincoff. “Abciximab reduces procedure time among patients undergoing percutaneous coronary intervention.” American Journal of Cardiology 84, no. 6A (September 22, 1999): 71P-71P.
       Link to Item
    • Madan, M., S. D. Berkowitz, D. J. Christie, L. K. Jennings, A. C. Smit, K. N. Sigmon, S. Glazer, and J. E. Tcheng. “Rapid assessment of GP IIb/IIIa blockade: An evaluation of PFA-100 (R) as a point-of-care technology during percutaneous coronary interventions (PCI)-checkpoint study.” Thrombosis and Haemostasis, August 1, 1999, 358–59.
       Link to Item
    • O’Shea, C., and J. E. Tcheng. “Platelet glycoprotein IIb/IIIa integrin inhibition in acute myocardial infarction.” J Invasive Cardiol 11, no. 8 (August 1999): 494–99.
       Link to Item
    • Lincoff, A. M., R. M. Califf, D. J. Moliterno, S. G. Ellis, J. Ducas, J. H. Kramer, N. S. Kleiman, et al. “Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.” N Engl J Med 341, no. 5 (July 29, 1999): 319–27. https://doi.org/10.1056/NEJM199907293410503.
       Full Text  Link to Item
    • Tcheng, J. E., D. J. Kereiakes, G. A. Braden, R. E. Jordan, M. A. Mascelli, M. A. Langrall, and M. B. Effron. “Readministration of abciximab: interim report of the ReoPro readministration registry.” Am Heart J 138, no. 1 Pt 2 (July 1999): S33–38. https://doi.org/10.1053/hj.1999.v138.99236.
       Full Text  Link to Item
    • Tcheng, J. E. “Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment.” Am J Cardiol 83, no. 9A (May 6, 1999): 7E-11E. https://doi.org/10.1016/s0002-9149(99)00084-3.
       Full Text  Link to Item
    • Lincoff, A. M., J. E. Tcheng, R. M. Califf, D. J. Kereiakes, T. A. Kelly, G. C. Timmis, N. S. Kleiman, et al. “Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.” Circulation 99, no. 15 (April 20, 1999): 1951–58. https://doi.org/10.1161/01.cir.99.15.1951.
       Full Text  Link to Item
    • Thel, M. C., R. M. Califf, J. E. Tcheng, K. N. Sigmon, A. M. Lincoff, E. J. Topol, and S. G. Ellis. “Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators.” Am Heart J 137, no. 2 (February 1999): 264–73. https://doi.org/10.1053/hj.1999.v137.92521.
       Full Text  Link to Item
    • Kleiman, N. S., and J. E. Tcheng. “Safety issues surrounding use of platelet GP IIb/IIIa antagonists: Reversibility and readministration.” European Heart Journal, Supplement 1, no. E (January 1, 1999).
    • Tardiff, B. E., R. M. Califf, J. E. Tcheng, A. M. Lincoff, K. N. Sigmon, R. A. Harrington, K. W. Mahaffey, et al. “Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II.” J Am Coll Cardiol 33, no. 1 (January 1999): 88–96. https://doi.org/10.1016/s0735-1097(98)00551-8.
       Full Text  Link to Item
    • Kong, D. F., R. M. Califf, D. P. Miller, D. J. Moliterno, H. D. White, R. A. Harrington, J. E. Tcheng, A. M. Lincoff, V. Hasselblad, and E. J. Topol. “Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease.” Circulation 98, no. 25 (December 22, 1998): 2829–35. https://doi.org/10.1161/01.cir.98.25.2829.
       Full Text  Link to Item
    • Madan, M., S. D. Berkowitz, and J. E. Tcheng. “Glycoprotein IIb/IIIa integrin blockade.” Circulation 98, no. 23 (December 8, 1998): 2629–35. https://doi.org/10.1161/01.cir.98.23.2629.
       Full Text  Link to Item
    • “Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial.” J Am Coll Cardiol 32, no. 7 (December 1998): 2003–10. https://doi.org/10.1016/s0735-1097(98)00474-4.
       Full Text  Link to Item
    • Ellis, S. G., A. M. Lincoff, D. Miller, J. E. Tcheng, N. S. Kleiman, D. Kereiakes, R. Califf, and E. J. Topol. “Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade.” J Am Coll Cardiol 32, no. 6 (November 15, 1998): 1619–23. https://doi.org/10.1016/s0735-1097(98)00403-3.
       Full Text  Link to Item
    • Bhatt, D. L., A. M. Lincoff, D. J. Kereiakes, J. E. Tcheng, M. L. Simoons, L. R. van der Wieken, N. Godfrey, R. M. Califf, and E. J. Topol. “Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention.” Am J Cardiol 82, no. 9 (November 1, 1998): 1105-A6. https://doi.org/10.1016/s0002-9149(98)00565-7.
       Full Text  Link to Item
    • Blankenship, J. C., N. K. Godfrey, G. Balog, S. L. Demko, and J. E. Tcheng. “How did Aciximab decrease ischemic complications during coronary intervention in EPISTENT? Analysis of in-lab adverse events.” Circulation 98, no. 17 (October 27, 1998): 573–573.
       Link to Item
    • Gilchrist, I. C., M. C. Thel, D. Joseph, H. E. Zimmerman, L. K. Jennings, N. S. Kleiman, D. J. Kerelakes, et al. “Enhanced platelet IIb/IIIa inhibition with eptifibatide via high-dose, double-bolus dosing: Final results of the PRIDE study.” Circulation 98, no. 17 (October 27, 1998): 844–45.
       Link to Item
    • Lincoff, A. M., J. E. Tcheng, R. M. Califf, C. F. Cabot, J. E. Booth, N. K. Godfrey, and E. J. Topol. “The EPISTENT trial at 6 months: Relative and combined effects of abciximab and stenting on reduction of acute ischemic events and late revascularization.” Circulation 98, no. 17 (October 27, 1998): 767–767.
       Link to Item
    • Tcheng, J. E., D. J. Kereiakes, G. A. Braden, A. M. Lincoff, M. A. Mascelli, M. A. Langrall, L. V. Damaraju, A. R. Schantz, E. S. Barnathan, and M. B. Effron. “Safety of abciximab retreatment - Final clinical report of the ReoPro readministration registry (R-3).” Circulation 98, no. 17 (October 27, 1998): 17–17.
       Link to Item
    • Kereiakes, D. J., A. M. Lincoff, M. L. Simoons, M. J. deBoer, J. E. Tcheng, A. Vahanian, K. M. Anderson, C. F. Cabot, and R. M. Califf. “Abciximab benefit in coronary intervention has no gender bias: Results of EPIC, EPILOG and CAPTURE trials.” American Journal of Cardiology 82, no. 7A (October 1, 1998): 95S-95S.
       Link to Item
    • Adelman, A. G., P. R. Caramori, E. A. Cohen, R. J. Chisholm, G. Côté, J. Ducas, B. J. O’Neill, and J. E. Tcheng. “The role of glycoprotein IIb/IIIa platelet inhibition in percutaneous coronary intervention in the stent era.” Can J Cardiol 14, no. 8 (August 1998): 1057–66.
       Link to Item
    • Berkowitz, S. D., D. C. Sane, K. N. Sigmon, J. H. Shavender, R. A. Harrington, J. E. Tcheng, E. J. Topol, and R. M. Califf. “Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group.” J Am Coll Cardiol 32, no. 2 (August 1998): 311–19. https://doi.org/10.1016/s0735-1097(98)00252-6.
       Full Text  Link to Item
    • EPISTENT Investigators, P. J. “Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.” Lancet 352, no. 9122 (July 11, 1998): 87–92. https://doi.org/10.1016/s0140-6736(98)06113-3.
       Full Text  Link to Item
    • Oesterle, S. N., J. A. Bittl, M. B. Leon, J. Hamburger, J. E. Tcheng, F. Litvack, J. Margolis, et al. “Laser wire for crossing chronic total occlusions: "learning phase" results from the U.S. TOTAL trial. Total Occlusion Trial With Angioplasty by Using a Laser Wire.” Cathet Cardiovasc Diagn 44, no. 2 (June 1998): 235–43. https://doi.org/10.1002/(sici)1097-0304(199806)44:2<235::aid-ccd23>3.0.co;2-k.
       Full Text  Link to Item
    • Mandak, J. S., J. C. Blankenship, L. H. Gardner, S. D. Berkowitz, F. V. Aguirre, K. N. Sigmon, G. C. Timmis, et al. “Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.” J Am Coll Cardiol 31, no. 7 (June 1998): 1518–24. https://doi.org/10.1016/s0735-1097(98)00130-2.
       Full Text  Link to Item
    • Pracyk, J. B., T. C. Wall, J. P. Longabaugh, F. D. Tice, J. Hochrein, C. Green, G. Cox, K. Lee, R. S. Stack, and J. E. Tcheng. “A randomized trial of vascular hemostasis techniques to reduce femoral vascular complications after coronary intervention.” Am J Cardiol 81, no. 8 (April 15, 1998): 970–76. https://doi.org/10.1016/s0002-9149(98)00074-5.
       Full Text  Link to Item
    • Kereiakes, D. J., A. M. Lincoff, D. P. Miller, J. E. Tcheng, C. F. Cabot, K. M. Anderson, H. F. Weisman, R. M. Califf, and E. J. Topol. “Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators.” Circulation 97, no. 9 (March 10, 1998): 857–64. https://doi.org/10.1161/01.cir.97.9.857.
       Full Text  Link to Item
    • Madan, M., and J. E. Tcheng. “Platelet Glycoprotein IIb/IIIa Integrin Blockade: Focus on Acute Myocardial Infarction.” J Invasive Cardiol 10 Suppl A (March 1998): 27A-32A.
       Link to Item
    • Kereiakes, D. “Abciximab Associated Thrombocytopenia: Evidence for a Complex Interaction With Heparin.” Journal of the American College of Cardiology 31, no. 2 (February 1998): 55A-55A. https://doi.org/10.1016/s0735-1097(97)83946-0.
       Full Text
    • Kereiakes, D. “Complementarity of Stenting and Abciximab for Percutaneous Coronary Intervention.” Journal of the American College of Cardiology 31, no. 2 (February 1998): 54A-54A. https://doi.org/10.1016/s0735-1097(97)83943-5.
       Full Text
    • Tcheng, J. “Safety of Readministration of Abciximab; Interim Results of the ReoPro Readministration Registry (R3).” Journal of the American College of Cardiology 31, no. 2 (February 1998): 55A-55A. https://doi.org/10.1016/s0735-1097(97)83944-7.
       Full Text
    • Van Wart, S., T. Kosoglou, J. E. Tcheng, T. Lorenz, K. Alton, B. Belanger, and E. Radwanski. “Eptifibatide pharmacokinetics in patients undergoing coronary angioplasty.” Clinical Pharmacology & Therapeutics 63, no. 2 (February 1, 1998): 232–232.
       Link to Item
    • Tcheng, J. E. “Perspectives on the future of platelet glycoprotein IIb/IIIa blockade therapy.” Tex Heart Inst J 25, no. 1 (1998): 49–56.
       Link to Item
    • Holmes, D. R., S. Mehta, C. J. George, J. R. Margolis, M. B. Leon, J. M. Isner, J. A. Bittl, et al. “Excimer laser coronary angioplasty: the New Approaches to Coronary Intervention (NACI) experience.” Am J Cardiol 80, no. 10A (November 20, 1997): 99K-105K. https://doi.org/10.1016/s0002-9149(97)00769-8.
       Full Text  Link to Item
    • Berkowitz, S. D., R. A. Harrington, M. M. Rund, and J. E. Tcheng. “Acute profound thrombocytopenia after c7E3 fab therapy - Response.” Circulation 96, no. 10 (November 18, 1997): 3810–3810.
       Link to Item
    • Ferrari, E., M. Thiry, C. Touati, P. Gibelin, and M. Baudouy. “Acute profound thrombocytopenia after c7E3 Fab therapy.” Circulation 96, no. 10 (November 18, 1997): 3809–10.
       Link to Item
    • Aguirre, F. V., M. L. Simoons, J. J. Ferguson, S. E. Fitzpatrick, K. M. Anderson, M. J. Kern, and J. E. Tcheng. “Impact of contrast media on clinical outcomes following percutaneous coronary interventions with platelet glycoprotein IIb/IIIa inhibition: Meta-analysis of clinical trials with abciximab.” Circulation 96, no. 8 (October 21, 1997): 898–898.
       Link to Item
    • Blankenship, J. C., K. M. Anderson, S. L. Demko, A. M. Lincoff, J. E. Tcheng, and C. F. Cabot. “In-lab angiographic complications during coronary intervention with abciximab vs placebo in the EPILOG trial.” Circulation 96, no. 8 (October 21, 1997): 905–905.
       Link to Item
    • Kereiakes, D. J., A. M. Lincoff, D. P. Miller, J. E. Tcheng, H. F. Weisman, and E. J. Topol. “Abciximab reduces risk of unplanned coronary stent deployment: Epilog trial results.” Circulation 96, no. 8 (October 21, 1997): 906–906.
       Link to Item
    • Lincoff, A. M., J. E. Tcheng, K. M. Anderson, and C. F. Cabot. “Durable inhibition of ischemic complications by abciximab during percutaneous coronary revascularization: One-year results of the EPILOG trial.” Circulation 96, no. 8 (October 21, 1997): 902–902.
       Link to Item
    • Madan, M., D. J. Kereiakes, M. Rund, L. Anderson, M. B. McDonald, G. Tudor, S. D. Berkowitz, M. H. Sketch, H. R. Phillips, and J. E. Tcheng. “Abciximab readministration for coronary interventions: Is it safe?” Circulation 96, no. 8 (October 21, 1997): 901–901.
       Link to Item
    • White, H. D., J. E. Tcheng, R. A. Harrington, D. Phillips, and N. S. Kleiman. “Roundtable panel discussion: The role of glycoprotein IIb-IIIa receptor inhibitors in acute ischemic coronary syndromes.” American Journal of Cardiology 80, no. 4 A (September 12, 1997). https://doi.org/10.1016/S0002-9149(97)00577-8.
       Full Text
    • Tcheng, J. E. “Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.” Am J Cardiol 80, no. 4A (August 18, 1997): 21B-28B. https://doi.org/10.1016/s0002-9149(97)00573-0.
       Full Text  Link to Item
    • White, H. D. “Roundtable panel discussion: the role of glycoprotein IIb-IIIa receptor inhibitors in acute ischemic coronary syndromes.” Am J Cardiol 80, no. 4A (August 18, 1997): 44B-48B.
       Link to Item
    • Topol, E. J., J. J. Ferguson, H. F. Weisman, J. E. Tcheng, S. G. Ellis, N. S. Kleiman, R. J. Ivanhoe, et al. “Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.” Jama 278, no. 6 (August 13, 1997): 479–84. https://doi.org/10.1001/jama.278.6.479.
       Full Text  Link to Item
    • Tcheng, J. E. “Platelet glycoprotein IIb/IIIa integrin blockade: recent clinical trials in interventional cardiology.” Thromb Haemost 78, no. 1 (July 1997): 205–9.
       Link to Item
    • EPILOG Investigators, N. B. “Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.” N Engl J Med 336, no. 24 (June 12, 1997): 1689–96. https://doi.org/10.1056/NEJM199706123362401.
       Full Text  Link to Item
    • “Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.” Lancet 349, no. 9063 (May 17, 1997): 1422–28.
       Link to Item
    • Puma, J. A., M. H. Sketch, J. E. Tcheng, L. H. Gardner, C. L. Nelson, H. R. Phillips, R. S. Stack, and R. M. Califf. “The natural history of single-vessel chronic coronary occlusion: a 25-year experience.” Am Heart J 133, no. 4 (April 1997): 393–99. https://doi.org/10.1016/s0002-8703(97)70179-0.
       Full Text  Link to Item
    • Berkowitz, S. D., R. A. Harrington, M. M. Rund, and J. E. Tcheng. “Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy.” Circulation 95, no. 4 (February 18, 1997): 809–13. https://doi.org/10.1161/01.cir.95.4.809.
       Full Text  Link to Item
    • Deckers, J., R. M. Califf, E. J. Topol, A. M. Lincoff, J. E. Tcheng, and M. L. Simoons. “Use of abciximab (ReoPro(R)) is not associated with an increase in the risk of stroke: Overview of three randomized trials.” Journal of the American College of Cardiology 29, no. 2 (February 1, 1997): 97489–97489.
       Link to Item
    • Ellis, S., A. M. Lincoff, J. E. Tcheng, D. P. Miller, J. E. Booth, R. M. Califf, and E. Topol. “Is there a differential benefit of ReoPro during PTCA for patients with certain lesion types?” Journal of the American College of Cardiology 29, no. 2 (February 1, 1997): 8012–8012.
       Link to Item
    • Krucoff, M. W., D. I. Landis, C. L. Green, A. K. Loeffler, E. Eisenstein, A. Moore, J. E. Tcheng, et al. “Upright posture with a flexible femoral sheath: Safety and cost results from 900 patients in the ''heads up'' trial.” Journal of the American College of Cardiology 29, no. 2 (February 1, 1997): 9938–9938.
       Link to Item
    • Lincoff, A. M., D. B. Mark, R. M. Califf, J. E. Tcheng, S. G. Ellis, L. DavidsonRay, K. M. Anderson, G. L. Stoner, and E. J. Topol. “Economic assessment of platelet glycoprotein IIb/IIa receptor blockade during coronary intervention in the EPILOG trial.” Journal of the American College of Cardiology 29, no. 2 (February 1, 1997): 97484–97484.
       Link to Item
    • Lincoff, A. M., J. E. Tcheng, R. M. Califf, C. F. Cabot, D. P. Miller, J. E. Booth, E. A. Montague, K. M. Anderson, and E. J. Topol. “Abciximab (c7E3 fab, ReoPro) with reduced heparin dosing during coronary intervention: Final results of the EPILOG trial.” Journal of the American College of Cardiology 29, no. 2 (February 1, 1997): 7396–7396.
       Link to Item
    • Tardiff, B. E., J. E. Tcheng, S. Peck, A. M. Lincoff, R. A. Harrington, R. M. Califf, and E. J. Topol. “Bleeding with coronary artery bypass surgery (CABG) in patients treated with a platelet glycoprotein IIb/IIIa inhibitor.” Journal of the American College of Cardiology 29, no. 2 (February 1, 1997): 52128–52128.
       Link to Item
    • Tcheng, J. E., A. M. Lincoff, D. P. Miller, J. E. Booth, M. M. Rund, C. F. Cabot, H. F. Weisman, R. M. Califf, and E. J. Topol. “Benefits of abciximab accrue in the full spectrum of coronary interventional patients: Insights from the EPILOG trial.” Journal of the American College of Cardiology 29, no. 2 (February 1, 1997): 9931–9931.
       Link to Item
    • Tcheng, J. E., K. Anderson, B. E. Tardiff, C. F. Cabot, A. M. Lincoff, R. M. Califf, and E. J. Topol. “Reducing the risk of percutaneous intervention after coronary bypass surgery: Beneficial effects of abciximab treatment.” Journal of the American College of Cardiology 29, no. 2 (February 1, 1997): 7395–7395.
       Link to Item
    • Thel, M. C., C. J. Davidson, F. V. Aguirre, S. L. Peck, J. E. Tcheng, A. M. Lincoff, E. J. Topol, and R. M. Califf. “What predicts contrast nephropathy after coronary intervention? Insights from the IMPACT II trial.” Journal of the American College of Cardiology 29, no. 2 (February 1, 1997): 8210–8210.
       Link to Item
    • Lincoff, A. M., J. E. Tcheng, R. M. Califf, T. Bass, J. J. Popma, P. S. Teirstein, N. S. Kleiman, et al. “Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators.” Am J Cardiol 79, no. 3 (February 1, 1997): 286–91. https://doi.org/10.1016/s0002-9149(96)00749-7.
       Full Text  Link to Item
    • Amsterdam, P. B., and J. E. Tcheng. “Platelet and thrombin inhibitors as adjuncts to thrombolytic therapy and percutaneous coronary interventions: A review.” Journal of Interventional Cardiology 10, no. 4 (January 1, 1997): 249–63. https://doi.org/10.1111/j.1540-8183.1997.tb00039.x.
       Full Text
    • Tan, H. C., R. A. Harrington, and J. E. Tcheng. “Platelet Glycoprotein IIb/IIIa Integrin Blockade in Coronary Artery Disease: Current State of the Art.” J Thromb Thrombolysis 4, no. 3/4 (1997): 431–39. https://doi.org/10.1023/a:1008809702729.
       Full Text  Link to Item
    • Berkowitz, S. D., R. A. Harrington, M. M. Rund, and J. E. Tcheng. “Acute profound thrombocytopenia following C7E3 FAB (abciximab) therapy.” Blood 88, no. 10 (November 15, 1996): 2055–2055.
       Link to Item
    • Aguirre, F. V., E. J. Topol, J. J. Ferguson, J. C. Blankenship, L. H. Gardner, E. A. Caracciolo, T. J. Donohue, R. A. Harrington, and J. E. Tcheng. “Effect of platelet glycoprotein (GP) IIb/IIIa antagonism with integrilin on activated clotting times during coronary interventions: Results from the IMPACT II trial.” Circulation 94, no. 8 (October 15, 1996): 1148–1148.
       Link to Item
    • Blankenship, J. C., K. N. Sigmon, B. E. Tardiff, S. L. Demko, and J. E. Tcheng. “Effect of glycoprotein IIb/IIIa receptor inhibition on specific in-lab complications of coronary intervention and resultant CKMB elevation in the IMPACT II trial.” Circulation 94, no. 8 (October 15, 1996): 1150–1150.
       Link to Item
    • Ghaffari, S., D. J. Kereiakes, T. Kelly, J. E. Tcheng, G. C. Timmis, D. P. Miller, and A. M. Lincoff. “Platelet GP IIb/IIIa receptor blockade reduces ischemic complications in patients undergoing directional coronary atherectomy.” Circulation 94, no. 8 (October 15, 1996): 1154–1154.
       Link to Item
    • Gilchrist, I. C., J. B. Muhlestein, R. J. Ivanhoe, L. H. Gardner, and J. E. Tcheng. “Does interventional volume or academic status affect outcome? Insights from the IMPACT-II trial.” Circulation 94, no. 8 (October 15, 1996): 1888–1888.
       Link to Item
    • Lincoff, A. M., J. E. Tcheng, D. P. Miller, J. E. Booth, E. A. Montague, and E. J. Topol. “Marked enhancement of clinical efficacy of platelet GP IIb/IIIa blockade with c7E3 fab (Abciximab) linked to reduction in bleeding complications: Outcome in the EPILOG and EPIC trials.” Circulation 94, no. 8 (October 15, 1996): 2185–2185.
       Link to Item
    • Pracyk, J. B., T. C. Wall, J. P. Longabaugh, F. D. Tice, J. Hochrein, G. C. Cox, K. L. Lee, and J. E. Tcheng. “Femoral vascular complications following coronary intervention: Is mechanical clamp hemostasis better than hand pressure?” Circulation 94, no. 8 (October 15, 1996): 2197–2197.
       Link to Item
    • Tan, H. C., M. H. Sketch, M. E. Tan, L. W. S. Sng, J. E. Tcheng, and J. P. Zidar. “Is there an optimal treatment strategy for stent restenosis?” Circulation 94, no. 8 (October 15, 1996): 522–522.
       Link to Item
    • Tcheng, J. E. “Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.” Am J Cardiol 78, no. 3A (August 14, 1996): 35–40. https://doi.org/10.1016/s0002-9149(96)00490-0.
       Full Text  Link to Item
    • Tcheng, J. E. “Saline infusion in excimer laser coronary angioplasty.” Semin Interv Cardiol 1, no. 2 (June 1996): 135–41.
       Link to Item
    • Narins, C. R., W. B. Hillegass, C. L. Nelson, J. E. Tcheng, R. A. Harrington, H. R. Phillips, R. S. Stack, and R. M. Califf. “Relation between activated clotting time during angioplasty and abrupt closure.” Circulation 93, no. 4 (February 15, 1996): 667–71. https://doi.org/10.1161/01.cir.93.4.667.
       Full Text  Link to Item
    • Sambol, N. C., J. E. Tcheng, M. Kitt, and T. Lorenz. “Population pharmacokinetics (PK) and pharmacodynamics (PD) of integrelin, a platelet aggregation inhibitor.” Clinical Pharmacology & Therapeutics 59, no. 2 (February 1, 1996): PI84–PI84.
       Link to Item
    • Tcheng, J. E. “Platelet Integrin Glycoprotein IIb/IIIa Inhibitors: Opportunities and Challenges.” J Invasive Cardiol 8 Suppl B (1996): 8B-14B.
       Link to Item
    • Tcheng, J. E. “Glycoprotein IIb/IIIa receptor inhibitors: Putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.” American Journal of Cardiology 78, no. 3 A (1996): 35–40.
    • Harrington, R. A., N. S. Kleiman, K. Kottke-Marchant, A. M. Lincoff, J. E. Tcheng, K. N. Sigmon, D. Joseph, G. Rios, K. Trainor, and D. Rose. “Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention.” Am J Cardiol 76, no. 17 (December 15, 1995): 1222–27. https://doi.org/10.1016/s0002-9149(99)80345-2.
       Full Text  Link to Item
    • Bittl, J. A., J. A. Brinker, T. A. Sanborn, J. M. Isner, and J. E. Tcheng. “The changing profile of patient selection, procedural techniques, and outcomes in excimer laser coronary angioplasty. Participating Investigators of the Percutaneous Excimer Laser Coronary Angioplasty Registry.” J Interv Cardiol 8, no. 6 (December 1995): 653–60. https://doi.org/10.1111/j.1540-8183.1995.tb00915.x.
       Full Text  Link to Item
    • Crenshaw, B. S., R. A. Harrington, and J. E. Tcheng. “Section review: Cardiovascular & renal: Novel antiplatelet agents: The glycoprotein IIb/IIIa inhibitors.” Expert Opinion on Investigational Drugs 4, no. 11 (November 1, 1995): 1033–44. https://doi.org/10.1517/13543784.4.11.1033.
       Full Text
    • Ohman, E. M., R. A. Harrington, A. M. Lincoff, M. M. Kitt, N. S. Kleiman, and J. E. Tcheng. “Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor.” Eur Heart J 16 Suppl L (November 1995): 50–55. https://doi.org/10.1093/eurheartj/16.suppl_l.50.
       Full Text  Link to Item
    • Califf, R. M., A. M. Lincoff, J. E. Tcheng, and E. J. Topol. “An overview of the results of the EPIC trial.” Eur Heart J 16 Suppl L (November 1995): 43–49. https://doi.org/10.1093/eurheartj/16.suppl_l.43.
       Full Text  Link to Item
    • HARRINGTON, R. A., E. M. OHMAN, K. N. SIGMON, N. S. KLEIMAN, S. P. SCHULMAN, K. KOTTKEMARCHANT, A. M. LINCOFF, et al. “INTENSITY OF INHIBITION OF THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR DIFFERS AMONG DISEASE STATES.” Circulation 92, no. 8 (October 15, 1995): 2333–2333.
       Link to Item
    • KRUSE, K. R., J. F. TANGUAY, B. A. ARMSTRONG, L. H. GARDNER, H. R. PHILLIPS, M. H. SKETCH, J. E. TCHENG, J. P. ZIDAR, and R. S. STACK. “LONG-TERM SURVIVAL AFTER MYOCARDIAL-INFARCTION IN PATIENTS WITH MULTIVESSEL CORONARY-DISEASE - A COMPARISON OF INFARCT-RELATED ARTERY (IRA) REVASCULARIZATION VERSUS TOTAL REVASCULARIZATION (TR).” Circulation 92, no. 8 (October 15, 1995): 356–356.
       Link to Item
    • LINCOFF, A. M., J. E. TCHENG, S. G. ELLIS, D. J. MOLITERNO, M. M. KITT, D. DEBOWEY, and E. J. TOPOL. “RANDOMIZED TRIAL OF PLATELET GLYCOPROTEIN-IIB/GLYCOPROTEIN-IIIA INHIBITION WITH INTEGRELIN(TM) FOR PREVENTION OF RESTENOSIS FOLLOWING CORONARY INTERVENTION - THE IMPACT-II ANGIOGRAPHIC SUBSTUDY.” Circulation 92, no. 8 (October 15, 1995): 2905–2905.
       Link to Item
    • TCHENG, J. E., A. M. LINCOFF, K. N. SIGMON, M. M. KITT, R. M. CALIFF, and E. J. TOPOL. “PLATELET GLYCOPROTEIN-IIB/GLYCOPROTEIN-IIIA INHIBITION WITH INTEGRELIN(TM) DURING PERCUTANEOUS CORONARY INTERVENTION - THE IMPACT-II TRIAL.” Circulation 92, no. 8 (October 15, 1995): 2595–2595.
       Link to Item
    • O’Malley, C. M., E. K. Paulson, M. A. Kliewer, J. E. Tcheng, B. S. Hertzberg, and B. A. Carroll. “Color Doppler sonographic appearance of patent needle tracts after femoral arterial catheterization.” Radiology 197, no. 1 (October 1995): 163–65. https://doi.org/10.1148/radiology.197.1.7568817.
       Full Text  Link to Item
    • Paulson, E. K., M. A. Kliewer, B. S. Hertzberg, J. E. Tcheng, R. L. McCann, J. D. Bowie, and B. A. Carroll. “Ultrasonographically guided manual compression of femoral artery injuries.” J Ultrasound Med 14, no. 9 (September 1995): 653–59. https://doi.org/10.7863/jum.1995.14.9.653.
       Full Text  Link to Item
    • Tcheng, J. E. “Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents.” Am Heart J 130, no. 3 Pt 2 (September 1995): 673–79. https://doi.org/10.1016/0002-8703(95)90305-4.
       Full Text  Link to Item
    • Strauss, B. H., M. K. Natarajan, W. B. Batchelor, D. E. Yardley, J. A. Bittl, T. A. Sanborn, J. A. Power, L. E. Watson, R. Moothart, and J. E. Tcheng. “Early and late quantitative angiographic results of vein graft lesions treated by excimer laser with adjunctive balloon angioplasty.” Circulation 92, no. 3 (August 1, 1995): 348–56. https://doi.org/10.1161/01.cir.92.3.348.
       Full Text  Link to Item
    • Puma, J. A., M. H. Sketch, J. E. Tcheng, R. A. Harrington, H. R. Phillips, R. S. Stack, and R. M. Califf. “Percutaneous revascularization of chronic coronary occlusions: an overview.” J Am Coll Cardiol 26, no. 1 (July 1995): 1–11. https://doi.org/10.1016/0735-1097(95)00156-t.
       Full Text  Link to Item
    • Tcheng, J. E., R. A. Harrington, K. Kottke-Marchant, N. S. Kleiman, S. G. Ellis, D. J. Kereiakes, M. J. Mick, F. I. Navetta, J. E. Smith, and S. J. Worley. “Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators.” Circulation 91, no. 8 (April 15, 1995): 2151–57. https://doi.org/10.1161/01.cir.91.8.2151.
       Full Text  Link to Item
    • Tcheng, J. E. “Key References: Antiplatelet Therapy as an Adjunct to Thrombolysis and Coronary Angioplasty.” J Thromb Thrombolysis 1, no. 2 (1995): 213–16. https://doi.org/10.1007/BF01062581.
       Full Text  Link to Item
    • Tcheng, J. E. “Trials of interventional devices.” Journal of Myocardial Ischemia 7, no. 5 (January 1, 1995): 214–20.
    • Tcheng, J. E., L. D. Wells, H. R. Phillips, L. I. Deckelbaum, and R. A. Golobic. “Development of a new technique for reducing pressure pulse generation during 308-nm excimer laser coronary angioplasty.” Cathet Cardiovasc Diagn 34, no. 1 (January 1995): 15–22. https://doi.org/10.1002/ccd.1810340306.
       Full Text  Link to Item
    • KRUCOFF, M. W., R. H. JONES, C. M. OCONNOR, S. W. CRATER, C. L. GREEN, M. B. HIGGINBOTHAM, J. P. ZIDAR, J. E. TCHENG, R. S. STACK, and R. M. CALIFF. “THE HIGH-RISK MYOCARDIAL-ISCHEMIA TRIAL (HIRMIT) RANDOMIZED PILOT AND REGISTRY - 6 DAY, 6 WEEK, 6 MONTH AND 1 YEAR MORTALITY.” Circulation 90, no. 4 (October 1, 1994): 334–334.
       Link to Item
    • RUND, M. M., D. D. SMITH, S. A. DELUCA, C. L. ROUSE, K. N. SIGMON, N. B. JURAN, M. OBRIEN, and J. E. TCHENG. “HEPARIN DURING CORONARY ANGIOPLASTY - ARE THERE ANY RULES.” Circulation 90, no. 4 (October 1, 1994): 487–487.
       Link to Item
    • Tcheng, J. E., S. G. Ellis, B. S. George, D. J. Kereiakes, N. S. Kleiman, J. D. Talley, A. L. Wang, H. F. Weisman, R. M. Califf, and E. J. Topol. “Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.” Circulation 90, no. 4 (October 1994): 1757–64. https://doi.org/10.1161/01.cir.90.4.1757.
       Full Text  Link to Item
    • Tenaglia, A. N., D. F. Fortin, R. M. Califf, D. J. Frid, C. L. Nelson, L. Gardner, M. Miller, F. I. Navetta, J. E. Smith, and J. E. Tcheng. “Predicting the risk of abrupt vessel closure after angioplasty in an individual patient.” J Am Coll Cardiol 24, no. 4 (October 1994): 1004–11. https://doi.org/10.1016/0735-1097(94)90862-1.
       Full Text  Link to Item
    • Bittl, J. A., T. A. Sanborn, D. E. Yardley, J. E. Tcheng, J. M. Isner, S. K. Chokshi, B. H. Strauss, G. S. Abela, P. D. Walter, and M. Schmidhofer. “Predictors of outcome of percutaneous excimer laser coronary angioplasty of saphenous vein bypass graft lesions. The Percutaneous Excimer Laser Coronary Angioplasty Registry.” Am J Cardiol 74, no. 2 (July 15, 1994): 144–48. https://doi.org/10.1016/0002-9149(94)90087-6.
       Full Text  Link to Item
    • Brodie, B. R., C. L. Grines, R. Ivanhoe, W. Knopf, G. Taylor, J. O’Keefe, R. A. Weintraub, L. G. Berdan, J. E. Tcheng, and L. H. Woodlief. “Six-month clinical and angiographic follow-up after direct angioplasty for acute myocardial infarction. Final results from the Primary Angioplasty Registry.” Circulation 90, no. 1 (July 1994): 156–62. https://doi.org/10.1161/01.cir.90.1.156.
       Full Text  Link to Item
    • Baumbach, A., J. A. Bittl, E. Fleck, H. J. Geschwind, T. A. Sanborn, J. E. Tcheng, and K. R. Karsch. “Acute complications of excimer laser coronary angioplasty: a detailed analysis of multicenter results. Coinvestigators of the U.S. and European Percutaneous Excimer Laser Coronary Angioplasty (PELCA) Registries.” J Am Coll Cardiol 23, no. 6 (May 1994): 1305–13. https://doi.org/10.1016/0735-1097(94)90371-9.
       Full Text  Link to Item
    • Mark, D. B., C. L. Nelson, R. M. Califf, F. E. Harrell, K. L. Lee, R. H. Jones, D. F. Fortin, R. S. Stack, D. D. Glower, and L. R. Smith. “Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty.” Circulation 89, no. 5 (May 1994): 2015–25. https://doi.org/10.1161/01.cir.89.5.2015.
       Full Text  Link to Item
    • Topol, E. J., R. M. Califf, H. F. Weisman, S. G. Ellis, J. E. Tcheng, S. Worley, R. Ivanhoe, B. S. George, D. Fintel, and M. Weston. “Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators.” Lancet 343, no. 8902 (April 9, 1994): 881–86. https://doi.org/10.1016/s0140-6736(94)90007-8.
       Full Text  Link to Item
    • Arie, S., J. E. Tcheng, D. P. Garcia, H. Checchi, P. Horta, A. Esteves Filho, A. N. Souza, F. S. de Brito Júnior, G. Bellotti, and F. Pileggi. “[Laser coronary angioplasty. Critical analysis of the first patients].” Arq Bras Cardiol 62, no. 4 (April 1994): 225–32.
       Link to Item
    • O’Neill, W. W., B. R. Brodie, R. Ivanhoe, W. Knopf, G. Taylor, J. O’Keefe, C. L. Grines, R. Weintraub, B. G. Sickinger, and L. G. Berdan. “Primary coronary angioplasty for acute myocardial infarction (the Primary Angioplasty Registry).” Am J Cardiol 73, no. 9 (April 1, 1994): 627–34. https://doi.org/10.1016/0002-9149(94)90924-5.
       Full Text  Link to Item
    • HARRINGTON, R. A., K. MARCHANT, N. S. KLEIMAN, J. D. LEIMBERGER, J. E. TCHENG, K. N. SIGMON, D. D. SMITH, M. KITT, E. J. TOPOL, and R. M. CALIFF. “BLEEDING ASSOCIATED WITH USE OF A PLATELET GLYCOPROTEIN IIBIIA INHIBITOR DURING ROUTINE CORONARY ANGIOPLASTY - IS TOO MUCH HEPARIN THE CULPRIT.” Journal of the American College of Cardiology, February 1, 1994, A106–A106.
       Link to Item
    • HARRINGTON, R. A., K. MARCHANT, N. S. KLEIMAN, K. N. SIGMON, D. JOSEPH, J. PARKER, G. RIOS, et al. “IMMEDIATE, REVERSIBLE PLATELET-AGGREGATION INHIBITION IN PATIENTS UNDERGOING CORONARY ANGIOPLASTY.” Journal of the American College of Cardiology, February 1, 1994, A106–A106.
       Link to Item
    • MUHLESTEIN, J. B., M. H. SKETCH, A. N. TENAGLIA, J. P. ZIDAR, D. F. FORTIN, T. D. BOONE, J. E. TCHENG, H. R. PHILLIPS, and R. S. STACK. “DOES THE USE OF HIGH INFLATION PRESSURES ADVERSELY AFFECT THE ACUTE AND LONG-TERM OUTCOME OF CORONARY ANGIOPLASTY.” Journal of the American College of Cardiology, February 1, 1994, A352–A352.
       Link to Item
    • PUMA, J. A., M. H. SKETCH, J. E. TCHENG, L. H. GARDNER, C. L. NELSON, H. R. PHILLIPS, R. S. STACK, and R. M. CALIFF. “CHRONIC TOTAL CORONARY-OCCLUSION OF AN ISOLATED VESSEL IN 891 PATIENTS OVER 24 YEARS - IS MEDICAL-MANAGEMENT AND ADEQUATE APPROACH.” Journal of the American College of Cardiology, February 1, 1994, A390–A390.
       Link to Item
    • STRAUSS, B. H., M. K. NATARAJAN, W. B. BATCHELOR, D. E. YARDLEY, T. A. SANBOM, J. A. POWER, L. E. WATSON, et al. “QUANTITATIVE ANGIOGRAPHIC ANALYSIS OF VEIN GRAFT LESIONS TREATED WITH EXCIMER-LASER ANGIOPLASTY - IMMEDIATE AND FOLLOW-UP RESULTS.” Journal of the American College of Cardiology, February 1, 1994, A449–A449.
       Link to Item
    • Arie, S., J. E. Tcheng, D. P. Garcia, H. Checchi, P. Horta, A. Esteves Filho, A. N. Souza, F. S. de Brito Júnior, G. Bellotti, and F. Pileggi. “Laser coronary angioplasty. Critical analysis of the first patients.” Arquivos Brasileiros De Cardiologia 62, no. 4 (January 1, 1994): 225–32.
    • KEREIAKES, D., J. J. FERGUSON, J. J. POPMA, R. E. SHAW, J. E. TCHENG, H. WEISMAN, A. M. LINCOFF, K. BREZINA, and F. AGUIRRE. “UNTITLED.” Journal of Invasive Cardiology 6 (January 1, 1994): A43–56.
       Link to Item
    • TCHENG, J. E. “Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.” Circulation 90 (1994): 1757–64.
    • Tcheng, J. E. “Dosing and administration of ReoPro (c7E3 Fab).” J Invasive Cardiol 6 Suppl A (1994): 29A-33A.
       Link to Item
    • BITTL, J. A., J. E. TCHENG, and T. A. SANBORN. “THE CHANGING PROFILE OF PATIENTS AND LESIONS TREATED WITH PERCUTANEOUS EXCIMER-LASER CORONARY ANGIOPLASTY - 1989 TO 1993.” Circulation 88, no. 4 (October 1, 1993): 23–23.
       Link to Item
    • BITTL, J. A., T. A. SANBORN, J. E. TCHENG, and L. E. WATSON. “EXCIMER LASER-FACILITATED ANGIOPLASTY FOR UNDILATABLE CORONARY LESIONS - RESULTS OF A PROSPECTIVE CONTROLLED-STUDY.” Circulation 88, no. 4 (October 1, 1993): 24–24.
       Link to Item
    • HARRINGTON, R. A., G. RIOS, N. S. KLEIMAN, K. SIGMON, D. C. SANE, J. E. TCHENG, C. MERCADO, R. SWIFT, and M. KITT. “PLATELET-FUNCTION DURING INTEGRELIN ADMINISTRATION IN CORONARY ANGIOPLASTY.” Circulation 88, no. 4 (October 1, 1993): 319–319.
       Link to Item
    • RESAR, J. R., J. A. BITTL, J. E. TCHENG, L. I. DECKELBAUM, and J. A. BRINKER. “PERCUTANEOUS EXCIMER-LASER CORONARY ANGIOPLASTY WITH ECCENTRIC MONORAIL CATHETERS.” Circulation 88, no. 4 (October 1, 1993): 24–24.
       Link to Item
    • TCHENG, J. E., E. J. TOPOL, N. S. KLEIMAN, S. G. ELLIS, F. I. NAVETTA, D. J. FINTEL, H. F. WEISMAN, et al. “IMPROVEMENT IN CLINICAL OUTCOMES OF CORONARY ANGIOPLASTY BY TREATMENT WITH THE GPIIB/IIIA INHIBITOR CHIMERIC-7E3 - MULTIVARIABLE ANALYSIS OF THE EPIC STUDY.” Circulation 88, no. 4 (October 1, 1993): 506–506.
       Link to Item
    • TCHENG, J. E., J. E. ELLIS, N. S. KLEIMAN, R. A. HARRINGTON, M. J. MICK, F. I. NAVETTA, S. WORLEY, et al. “OUTCOME OF PATIENTS TREATED WITH THE GPIIB/IIIA INHIBITOR INTEGRELIN DURING CORONARY ANGIOPLASTY - RESULTS OF THE IMPACT STUDY.” Circulation 88, no. 4 (October 1, 1993): 595–595.
       Link to Item
    • Tenaglia, A. N., D. F. Fortin, D. J. Frid, L. H. Gardner, C. L. Nelson, J. E. Tcheng, R. S. Stack, and R. M. Califf. “Long-term outcome following successful reopening of abrupt closure after coronary angioplasty.” Am J Cardiol 72, no. 1 (July 1, 1993): 21–25. https://doi.org/10.1016/0002-9149(93)90212-u.
       Full Text  Link to Item
    • Tenaglia, A. N., J. P. Zidar, J. D. Jackman, D. F. Fortin, M. W. Krucoff, J. E. Tcheng, H. R. Phillips, and R. S. Stack. “Treatment of long coronary artery narrowings with long angioplasty balloon catheters.” Am J Cardiol 71, no. 15 (June 1, 1993): 1274–77. https://doi.org/10.1016/0002-9149(93)90539-o.
       Full Text  Link to Item
    • Bittl, J. A., T. J. Ryan, J. F. Keaney, J. E. Tcheng, S. G. Ellis, J. M. Isner, and T. A. Sanborn. “Coronary artery perforation during excimer laser coronary angioplasty. The percutaneous Excimer Laser Coronary Angioplasty Registry.” J Am Coll Cardiol 21, no. 5 (April 1993): 1158–65. https://doi.org/10.1016/0735-1097(93)90240-2.
       Full Text  Link to Item
    • Ellis, S. G., J. E. Tcheng, F. I. Navetta, D. W. Muller, H. F. Weisman, C. Smith, K. M. Anderson, R. M. Califf, and E. J. Topol. “Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty.” Coron Artery Dis 4, no. 2 (February 1993): 167–75. https://doi.org/10.1097/00019501-199302000-00007.
       Full Text  Link to Item
    • Tcheng, J. E., J. D. Jackman, C. L. Nelson, L. H. Gardner, L. R. Smith, J. S. Rankin, R. M. Califf, and R. S. Stack. “Does reperfusion improve prognosis when mitral regurgitation complicates infarction?” Cardiology Board Review 10, no. 8 (January 1, 1993): 17–22.
    • Tcheng, J. E., J. D. Jackman, R. M. Califf, and R. S. Stack. “Managing myocardial infarction complicated by mitral regurgitation.” Primary Cardiology 19, no. 10 (January 1, 1993): 40–48.
    • Bittl, J. A., T. A. Sanborn, J. E. Tcheng, R. M. Siegel, and S. G. Ellis. “Clinical success, complications and restenosis rates with excimer laser coronary angioplasty. The Percutaneous Excimer Laser Coronary Angioplasty Registry.” Am J Cardiol 70, no. 20 (December 15, 1992): 1533–39. https://doi.org/10.1016/0002-9149(92)90453-6.
       Full Text  Link to Item
    • Tcheng, J. E., J. S. Miller, R. W. Songer, and R. A. Golobic. “Percutaneous excimer laser coronary angioplasty: development of technology and initial clinical results.” Proceedings of Spie  the International Society for Optical Engineering 1642 (December 1, 1992): 98–109.
    • BAUMBACH, A., J. A. BITTL, E. FLECK, H. J. GESCHWIND, T. A. SANBORN, J. E. TCHENG, and K. R. KARSCH. “ACUTE COMPLICATIONS OF CORONARY EXCIMER LASER ANGIOPLASTY - ANALYSIS OF 2 MULTICENTER REGISTRIES.” Circulation 86, no. 4 (October 1, 1992): 510–510.
       Link to Item
    • BITTL, J. A., T. A. SANBORN, J. E. TCHENG, J. F. KEANEY, P. ESTELLA, and T. J. RYAN. “RISK OF CORONARY-ARTERY PERFORATION DURING EXCIMER LASER ANGIOPLASTY.” Circulation 86, no. 4 (October 1, 1992): 654–654.
       Link to Item
    • ELLIS, S. G., A. Z. ARNOLD, R. E. RAYMOND, N. L. EIGLER, T. A. SANBORN, J. A. BITTL, A. M. LINCOFF, M. R. MOONEY, J. E. TCHENG, and E. J. TOPOL. “INCREASED CORONARY PERFORATION IN THE NEW DEVICE ERA - INCIDENCE, CLASSIFICATION, MANAGEMENT AND OUTCOME.” Circulation 86, no. 4 (October 1, 1992): 787–787.
       Link to Item
    • TCHENG, J. E., J. A. BITTL, T. A. SANBORN, R. M. SIEGEL, R. GINSBURG, J. A. POWER, E. D. COHEN, W. P. BIDDLE, and J. D. JACKMAN. “TREATMENT OF AORTOOSTIAL DISEASE WITH PERCUTANEOUS EXCIMER LASER CORONARY ANGIOPLASTY.” Circulation 86, no. 4 (October 1, 1992): 512–512.
       Link to Item
    • TENAGLIA, A. N., J. E. TCHENG, K. B. KISSLO, J. A. PEREZ, H. R. PHILLIPS, and C. J. DAVIDSON. “INTRACORONARY ULTRASOUND EVALUATION OF EXCIMER LASER ANGIOPLASTY.” Circulation 86, no. 4 (October 1, 1992): 516–516.
       Link to Item
    • Muhlestein, J. B., P. J. Quigley, E. M. Ohman, R. P. Bauman, M. H. Sketch, J. E. Tcheng, C. J. Davidson, R. H. Peter, V. S. Behar, and M. W. Krucoff. “Prospective analysis of possible myocardial damage or hemolysis occurring as a result of prolonged autoperfusion angioplasty in humans.” J Am Coll Cardiol 20, no. 3 (September 1992): 594–98. https://doi.org/10.1016/0735-1097(92)90013-d.
       Full Text  Link to Item
    • Tenaglia, A. N., P. J. Quigley, D. J. Kereiakes, C. W. Abbottsmith, H. R. Phillips, J. E. Tcheng, D. Rendall, and E. M. Ohman. “Coronary angioplasty performed with gradual and prolonged inflation using a perfusion balloon catheter: procedural success and restenosis rate.” Am Heart J 124, no. 3 (September 1992): 585–89. https://doi.org/10.1016/0002-8703(92)90263-u.
       Full Text  Link to Item
    • Jackman, J. D., J. B. Hermiller, M. H. Sketch, C. J. Davidson, J. E. Tcheng, H. R. Phillips, and R. S. Stack. “Combined rotational and directional atherectomy guided by intravascular ultrasound in an occluded vein graft.” Am Heart J 124, no. 1 (July 1992): 214–16. https://doi.org/10.1016/0002-8703(92)90943-p.
       Full Text  Link to Item
    • Tcheng, J. E., J. D. Jackman, C. L. Nelson, L. H. Gardner, L. R. Smith, J. S. Rankin, R. M. Califf, and R. S. Stack. “Outcome of patients sustaining acute ischemic mitral regurgitation during myocardial infarction.” Ann Intern Med 117, no. 1 (July 1, 1992): 18–24. https://doi.org/10.7326/0003-4819-117-1-18.
       Full Text  Link to Item
    • Jackman, J. D., J. P. Zidar, J. E. Tcheng, A. B. Overman, H. R. Phillips, and R. S. Stack. “Outcome after prolonged balloon inflations of greater than 20 minutes for initially unsuccessful percutaneous transluminal coronary angioplasty.” Am J Cardiol 69, no. 17 (June 1, 1992): 1417–21. https://doi.org/10.1016/0002-9149(92)90893-4.
       Full Text  Link to Item
    • TCHENG, J. E. “Outcome of patients sustaining acute ischemic mitral regurgitation during myocardial infarction.” Ann Intern Med 117 (1992): 18–24.
    • Davidson, C. J., K. H. Sheikh, K. B. Kisslo, H. R. Phillips, R. H. Peter, V. S. Behar, Y. H. Kong, M. Krucoff, E. M. Ohman, and J. E. Tcheng. “Intracoronary ultrasound evaluation of interventional technologies.” Am J Cardiol 68, no. 13 (November 15, 1991): 1305–9. https://doi.org/10.1016/0002-9149(91)90236-e.
       Full Text  Link to Item
    • Jackman, J. D., F. I. Navetta, J. E. Smith, J. E. Tcheng, C. J. Davidson, H. R. Phillips, R. M. Califf, C. L. Nelson, L. H. Gardner, and R. S. Stack. “Percutaneous transluminal coronary angioplasty in octogenarians as an effective therapy for angina pectoris.” Am J Cardiol 68, no. 1 (July 1, 1991): 116–19. https://doi.org/10.1016/0002-9149(91)90724-y.
       Full Text  Link to Item
    • CALIFF, R. M., D. F. FORTIN, D. J. FRID, W. R. HARLAN, E. M. OHMAN, J. R. BENGTSON, C. L. NELSON, J. E. TCHENG, D. B. MARK, and R. S. STACK. “RESTENOSIS AFTER CORONARY ANGIOPLASTY - AN OVERVIEW.” Journal of the American College of Cardiology 17, no. 6 (May 1, 1991): B2–13.
       Link to Item
    • Califf, R. M., D. F. Fortin, D. J. Frid, W. R. Harlan, E. M. Ohman, J. R. Bengtson, C. L. Nelson, J. E. Tcheng, D. B. Mark, and R. S. Stack. “Restenosis after coronary angioplasty: an overview.” J Am Coll Cardiol 17, no. 6 Suppl B (May 1991): 2B-13B. https://doi.org/10.1016/0735-1097(91)90933-z.
       Full Text  Link to Item
    • Tenaglia, A. N., J. E. Tcheng, H. R. Phillips, and R. S. Stack. “Creation of pseudo narrowing during coronary angioplasty.” Am J Cardiol 67, no. 7 (March 15, 1991): 658–59. https://doi.org/10.1016/0002-9149(91)90913-6.
       Full Text  Link to Item
    • Cusma, J. T., L. A. Spero, K. G. Morris, J. E. Tcheng, and T. M. Bashore. “Quantitative analysis of cardiac images: Application in the clinical environment.” Medicamundi 36, no. 1 (January 1, 1991): 26–35.
    • FORTIN, D. F., D. J. FRID, C. NELSON, J. E. SMITH, R. F. RAMOS, W. R. HARLAN, and J. E. TCHENG. “THE IMPACT OF GENDER AND MENOPAUSAL STATUS ON RESTENOSIS AFTER ANGIOPLASTY.” Circulation 82, no. 4 (October 1, 1990): 624–624.
       Link to Item
    • FRID, D. J., D. F. FORTIN, L. C. LAM, W. R. HARLAN, F. I. NAVETTA, J. E. SMITH, R. RAMOS, C. NELSON, and J. E. TCHENG. “EFFECTS OF UNSTABLE SYMPTOMS ON RESTENOSIS.” Circulation 82, no. 4 (October 1, 1990): 427–427.
       Link to Item
    • NELSON, C. L., J. E. TCHENG, D. J. FRID, D. F. FORTIN, E. M. OHMAN, R. M. CALIFF, and R. S. STACK. “INCOMPLETE ANGIOGRAPHIC FOLLOW-UP RESULTS IN SIGNIFICANT UNDERESTIMATION OF TRUE RESTENOSIS RATES AFTER PTCA.” Circulation 82, no. 4 (October 1, 1990): 312–312.
       Link to Item
    • SKETCH, M. H., W. W. ONEILL, J. E. TCHENG, C. WALKER, J. P. GALICHIA, S. SAWCHAK, S. CRESS, H. R. PHILLIPS, and R. S. STACK. “EARLY AND LATE OUTCOME FOLLOWING CORONARY TRANSLUMINAL EXTRACTION-ENDARTERECTOMY - A MULTICENTER EXPERIENCE.” Circulation 82, no. 4 (October 1, 1990): 310–310.
       Link to Item
    • SMITH, J. E., F. I. NAVETTA, P. A. GURBEL, L. GARDNER, C. NELSON, P. HOFFMAN, D. RENDALL, and J. E. TCHENG. “CAN INTRACORONARY UROKINASE SALVAGE VESSEL PATENCY AFTER FAILED INTRAVENOUS-TPA AND PREVENT THE NEED FOR RESCUE PTCA.” Circulation 82, no. 4 (October 1, 1990): 537–537.
       Link to Item
    • TCHENG, J. E., D. F. FORTIN, D. J. FRID, C. L. NELSON, D. S. RENDALL, K. L. LEE, and R. S. STACK. “CONDITIONAL PROBABILITIES OF RESTENOSIS FOLLOWING CORONARY ANGIOPLASTY.” Circulation 82, no. 4 (October 1, 1990): 1–1.
       Link to Item
    • TCHENG, J. E., J. D. JACKMAN, L. H. GARDNER, C. L. NELSON, R. P. BAUMAN, L. R. SMITH, and J. S. RANKIN. “OPTIMIZATION OF LONG-TERM OUTCOME IN ACUTE MITRAL REGURGITATION DUE TO MYOCARDIAL-INFARCTION.” Circulation 82, no. 4 (October 1, 1990): 511–511.
       Link to Item
    • LUNDERGAN, C. F., M. L. FOEGH, P. QUIGLEY, J. E. TCHENG, and P. W. RAMWELL. “EFFECT OF ANGIOPEPTIN ON ATHEROGENESIS IN CYNOMOLGOUS MACAQUES.” Arteriosclerosis 10, no. 5 (September 1, 1990): A815–A815.
       Link to Item
    • STACK, R. S., R. M. CALIFF, H. R. PHILLIPS, D. B. PRYOR, P. J. QUIGLEY, R. P. BAUMAN, J. E. TCHENG, and J. C. GREENFIELD. “INTERVENTIONAL CARDIAC-CATHETERIZATION AT DUKE-MEDICAL-CENTER.” American Journal of Cardiology 62, no. 10 (October 1, 1988): F3–24.
       Link to Item
    • Stack, R. S., R. M. Califf, H. R. Phillips, D. B. Pryor, P. J. Quigley, R. P. Bauman, J. E. Tcheng, and J. C. Greenfield. “Interventional cardiac catheterization at Duke Medical Center.” Am J Cardiol 62, no. 10 Pt 2 (October 1, 1988): 3F-24F.
       Link to Item
    • Stack, R. S., R. M. Califf, H. R. Phillips, D. B. Pryor, P. J. Quigley, R. P. Bauman, J. E. Tcheng, and J. C. G. Jr. “Balloon angioplasty in acute myocardial infarction - Limitations of thrombolytic therapy when used alone.” American Journal of Cardiology 62, no. 10 PART II (1988): 4F-4F.
    • Stack, R. S., R. M. Califf, H. R. Phillips, D. B. Pryor, P. J. Quigley, R. P. Bauman, J. E. Tcheng, and J. C. Greenfield. “Interventional Cardiac Catheterization at Duke Medical Center - The Duke Interventional Cardiac Catheterization Program.” American Journal of Cardiology 62, no. 10 PART II (January 1, 1988).
    • Stack, R. S., R. M. Califf, H. R. Phillips, D. B. Pryor, P. J. Quigley, R. P. Bauman, J. E. Tcheng, and J. C. Greenfield. “New international technology: The autoperfusion balloon catheter.” American Journal of Cardiology 62, no. 10 PART II (January 1, 1988).
    • Stack, R. S., R. M. Califf, H. R. Phillips, D. B. Pryor, P. J. Quigley, R. P. Bauman, J. E. Tcheng, and J. C. Greenfield. “Limitations of balloon angioplasty: Possible causes of restenosis.” American Journal of Cardiology 62, no. 10 PART II (January 1, 1988).
    • Kunkel, T. A., J. E. Tcheng, and R. R. Meyer. “Purification and properties of DNA polymerase-beta from guinea pig liver.” Biochim Biophys Acta 520, no. 2 (September 27, 1978): 302–16. https://doi.org/10.1016/0005-2787(78)90229-0.
       Full Text  Link to Item
    • Mosbaugh, D. W., T. A. Kunkel, D. M. Stalker, J. E. Tcheng, and R. R. Meyer. “Novikoff hepatoma deoxyribonucleic acid polymerase. Sensitivity of the beta-polymerase to sulfhydryl blocking agents.” Nucleic Acids Res 3, no. 9 (September 1976): 2341–52. https://doi.org/10.1093/nar/3.9.2341.
       Full Text  Link to Item

  • Book Sections

    • Tcheng, J. E., and David A. Cox. “Primary Coronary Intervention: The Technical Approach.” In Primary Angioplasty in Acute Myocardial Infarction, 47–47. Springer Science & Business Media, 2009.

  • Conference Papers

    • Tanaka, John, Harsh Patolia, Bruce Lobaugh, Candance Van Vleet, Igor Klem, Joseph Borawski, Pratik Doshi, et al. “TWO YEAR EXPERIENCE WITH HIGH-SENSITIVITY TROPONIN TESTING:INTERPRETATIVE VALUES FOR IMPROVING PATIENT DISPOSITION.” In Journal of the American College of Cardiology, 79:982–982, 2022.
       Link to Item
    • Denardo, Scott J., Xinru Ren, Cindy L. Green, Latasha Oxendine-Phillips, and James E. Tcheng. “Reducing Disparities in Coronary Interventional Outcomes in a Diverse, High Risk Population.” In Circulation, Vol. 138, 2018.
       Link to Item
    • Denardo, Scott J., Xinru Ren, Cindy L. Green, Latasha Oxendine-Phillips, and James E. Tcheng. “Antiplatelet Therapy Only (Without Anticoagulation) in Higher Risk Coronary Intervention With Very Short Infusion Glycoprotein Inhibitor.” In Circulation, Vol. 138, 2018.
       Link to Item
    • Tcheng, James E., Kensaku Kawamoto, Blackford Middleton, Jonathan M. Teich, and Scott Weingarten. “Optimizing Patient Care through Clinical Decision Support: Identification of Opportunities and Call to Action by the National Academy of Medicine.” In Amia. AMIA, 2017.
    • Denardo, Scott J., Paul L. Carpinone, David M. Vock, James E. Tcheng, Harry R. Phillips, III, Christopher D. Batich, and Carl J. Pepine. “DAMAGE TO POLYMER SURFACE AND DETACHMENT OF POLYMER FRAGMENTS DURING DELIVERY BALLOON EXPANSION OF DRUG-ELUTING STENTS: A PREVIOUSLY UNRECOGNIZED SOURCE FOR ADVERSE OUTCOMES.” In Journal of the American College of Cardiology, 59:E218–E218. Elsevier BV, 2012. https://doi.org/10.1016/s0735-1097(12)60219-8.
       Full Text
    • Mehta, Rajandra H., Kishore J. Harjai, Judy A. Boura, James E. Tcheng, Gregg W. Stone, and Cindy L. Grines. “Is Balloon Angioplasty without Stent Placement Adequate far Patients In Whom Early Coronary Artery Bypass Surgery Is Planned after Primary Percutaneous Coronary Intervention?” In Circulation, 118:S633–S633. LIPPINCOTT WILLIAMS & WILKINS, 2008.
       Link to Item
    • Dery, Jean-Pierre, Jeffrey Griffin, Karen S. Pieper, Robert A. Harrington, and James E. Tcheng. “Comparison of outcomes between patients undergoing percutaneous coronary stent implantation with eptifibatide and abciximab: An analysis using propensity score methods.” In American Journal of Cardiology, 100:41L-42L. EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC, 2007.
       Link to Item
    • Rabbani, LeRoy E., Jennifer Stant, Cindy L. Grines, David A. Cox, Eulogio Garcia, James E. Tcheng, John J. Griffin, et al. “Impact of thienopyridine administration prior to primary stealing in acute myocardial infarction.” In American Journal of Cardiology, 100:213L-213L. EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC, 2007.
       Link to Item
    • Deibele, Albert J., Lisa K. Jennings, Ajay J. Kirtane, Duane S. Pinto, David P. Slovut, Michael J. Lucca, Cathy Neva, James E. Tcheng, and C Michael Gibson. “Local platelet glycoprotein IIb/IIIa receptor occupancy with intracoronary eptitibatide during stenting, the ICE pilot trial.” In American Journal of Cardiology, 98:45M-45M. EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC, 2006.
       Link to Item
    • Denardo, J., K. E. Davis, and J. E. Tcheng. “Low dose enoxaparin in non-ST segment elevation acute coronary syndrome, followed by antiplatelet therapy alone during subsequent percutaneous coronary intervention.” In European Heart Journal, 27:645–46. OXFORD UNIV PRESS, 2006.
       Link to Item
    • Halabi, A. R., E. F. Honeycutt, A. L. Stebbins, R. H. Mehta, M. H. Sketch, E. D. Peterson, K. S. Pieper, et al. “A contemporary risk score for the prediction of long-term mortality following percutaneous coronary intervention with stent implantation: The duke PCI risk score.” In Circulation, 112:U674–75. LIPPINCOTT WILLIAMS & WILKINS, 2005.
       Link to Item
    • Nikolsky, E., R. Mehran, C. L. Grines, M. Turco, T. Park, D. A. Cox, J. E. Tcheng, et al. “Higher baseline platelet count predicts reinfarction and death in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction: Analysis from the CADILLAC trial.” In Circulation, 112:U759–U759. LIPPINCOTT WILLIAMS & WILKINS, 2005.
       Link to Item
    • Simon, D. I., P. Burton, T. Palabrica, and J. E. Tcheng. “Impact of eptifibatide therapy on outcome in patients undergoing multiple stent insertion: An ESPRIT subanalysis.” In Circulation, 112:U633–U633. LIPPINCOTT WILLIAMS & WILKINS, 2005.
       Link to Item
    • Nikolsky, E., R. Mehran, C. L. Grines, M. Turco, D. A. Cox, J. E. Tcheng, B. R. Brodie, et al. “Impact of baseline platelet count on outcomes of patients undergoing primary percutaneous coronary intervention for acute myocardial infarction: Analysis from the CADILLAC trial.” In American Journal of Cardiology, 96:29H-29H. EXCERPTA MEDICA INC, 2005.
       Link to Item
    • De Luca, G., H. Suryapranata, G. W. Stone, D. Antoniucci, J. E. Tcheng, F. J. Neumann, F. Van de Werf, E. M. Antman, and E. J. Topol. “Adjunctive abciximab to reperfusion therapy in patients with acute st-segment elevation myocardial infarction: A meta-analysis of randomized trials.” In Journal of the American College of Cardiology, 45:251A-251A. ELSEVIER SCIENCE INC, 2005.
       Link to Item
    • Nikolsky, E., C. L. Grines, D. A. Cox, T. Stuckey, E. Garcia, G. Guagliumi, J. E. Tcheng, et al. “Stroke after primary angioplasty in acute myocardial infarction: Analysis from the CADILLAC trial.” In Journal of the American College of Cardiology, 45:52A-53A. ELSEVIER SCIENCE INC, 2005.
       Link to Item
    • Nikolsky, E., M. Singh, C. L. Grines, J. E. Tcheng, E. Garcia, D. A. Cox, M. Turco, et al. “Prediction of mortality following primary percutaneous coronary intervention for acute myocardial infarction: The CADILLAC risk score.” In Journal of the American College of Cardiology, 45:347A-347A. ELSEVIER SCIENCE INC, 2005.
       Link to Item
    • Tsuchiya, Y., A. J. Lansky, R. Mehran, R. A. Costa, E. Cristea, M. Tarawali, M. Corral, et al. “Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction. Results from the CADILLAC trial.” In Journal of the American College of Cardiology, 45:87A-87A. ELSEVIER SCIENCE INC, 2005.
       Link to Item
    • Sorajja, P., A. Lansky, J. E. Tcheng, C. O. Costantini, M. McLaughlin, C. L. Grines, P. Zimetbaum, and B. J. Gersh. “Integration of ST-segment recovery and myocardial blush for prediction of survival after primary percutaneous coronary intervention in acute myocardial infarction.” In Circulation, 110:409–409. LIPPINCOTT WILLIAMS & WILKINS, 2004.
       Link to Item
    • Sorajja, P., J. E. Tcheng, G. Guagliumi, M. A. Turco, J. D. Carroll, B. Brodie, E. Garcia, C. L. Grines, D. A. Cox, and B. J. Gersh. “Adverse impact of multivessel disease on ST-segment recovery and clinical outcome in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction.” In Circulation, 110:663–663. LIPPINCOTT WILLIAMS & WILKINS, 2004.
       Link to Item
    • Halkin, A., M. Turco, D. A. Cox, T. D. Stuckey, E. Garcia, G. Guagliumi, R. Mehran, et al. “Outcomes of percutaneous coronary intervention in patients with acute myocardial infarction excluded from randomization: The CADILLAC Trial.” In American Journal of Cardiology, 94:234E-234E. EXCERPTA MEDICA INC, 2004.
       Link to Item
    • Kandzari, D. E., D. A. Cox, T. Stuckey, M. Turco, R. Mehran, B. J. Gersh, E. Garcia, et al. “Reperfusion success and prognosis in patients with anterior compared with nonanterior infarction: Insights from the CADILLAC trial.” In American Journal of Cardiology, 94:230E-231E. EXCERPTA MEDICA INC, 2004.
       Link to Item
    • Nikolsky, E., C. L. Grines, D. A. Cox, E. Garcia, R. Mehran, J. E. Tcheng, J. J. Griffin, et al. “Implications of stroke after primary angioplasty in acute myocardial infarction.” In American Journal of Cardiology, 94:200E-200E. EXCERPTA MEDICA INC, 2004.
       Link to Item
    • Sorajja, P., A. Lansky, C. L. Grines, C. Costantini, M. G. McLaughlin, J. E. Tcheng, B. J. Gersh, and G. W. Stone. “Prediction of survival after primary percutaneous coronary intervention by integration of ST-segment recovery and myocardial blush.” In American Journal of Cardiology, 94:237E-237E. EXCERPTA MEDICA INC, 2004.
       Link to Item
    • Sorajja, P., B. J. Gersh, D. A. Cox, M. A. Turco, J. E. Tcheng, J. D. Carroll, B. Brodie, et al. “Adverse impact of multivessel disease on ST-segment recovery and clinical outcome in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction.” In American Journal of Cardiology, 94:233E-233E. EXCERPTA MEDICA INC, 2004.
       Link to Item
    • Denardo, J. S., K. E. Davis, and J. E. Tcheng. “Adjunctive pharmacotherapy during higher risk percutaneous coronary intervention: Eptifibatide-based antiplatelet therapy accompanied by only limited, specific antithrombin therapy.” In Journal of the American College of Cardiology, 43:31A-31A. ELSEVIER SCIENCE INC, 2004.
       Link to Item
    • Halkin, Amir, Cindy L. Grines, David A. Cox, Eulogio Garcia, Roxana Mehran, James E. Tcheng, John J. Griffin, et al. “869-2 Impact of intravenous beta-blockade during primary percutaneous intervention on convalescent left ventricular function.” In Journal of the American College of Cardiology, 43:A303–4. Elsevier BV, 2004. https://doi.org/10.1016/s0735-1097(04)91284-3.
       Full Text
    • Nikolsky, Eugenia, Amir Halkin, Eve A. Aymong, Roxana Mehran, Alexandra Lansky, Cindy L. Grines, Mark Turco, et al. “801-3 Anemia worsens prognosis after primary angioplasty in acute myocardial infarction: Analysis from the CADILLAC trial.” In Journal of the American College of Cardiology, 43:A267–A267. Elsevier BV, 2004. https://doi.org/10.1016/s0735-1097(04)91134-5.
       Full Text
    • Nikolsky, Eugenia, Roxana Mehran, Alexandra J. Lansky, Cindy L. Grines, David A. Cox, Eulogio Garcia, James E. Tcheng, et al. “1002-82 Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction: The obesity paradox.” In Journal of the American College of Cardiology, 43:A244–A244. Elsevier BV, 2004. https://doi.org/10.1016/s0735-1097(04)91037-6.
       Full Text
    • Pellizzon, Gregory G., Steve P. Marso, Cindy L. Grines, David A. Cox, Eulogio Garcia, James E. Tcheng, John J. Griffin, et al. “1061-100 Predictors of reinfarction after ST elevation myocardial infarction and glycoprotein receptor blockade: Analysis from the CADILLAC trial.” In Journal of the American College of Cardiology, 43:A266–A266. Elsevier BV, 2004. https://doi.org/10.1016/s0735-1097(04)91131-x.
       Full Text
    • Dery, J. P., M. E. Campbell, J. C. O’Shea, J. Mathias, K. Pieper, G. Hafley, L. Kottmeyer, S. Greenberg, and J. E. Tcheng. “Administration of a loading dose amplifies the beneficial effect of thienopyridine pretreatment and complements the use of GP IIb/IIIa inhibitor therapy in patients undergoing percutaneous coronary intervention with stenting.” In Circulation, 108:374–374. LIPPINCOTT WILLIAMS & WILKINS, 2003.
       Link to Item
    • Exaire, J. E., J. E. Tcheng, D. J. Kereiakes, N. S. Kleiman, R. J. Applegate, and D. J. Moliterno. “Closure devices and vascular complications among PCI patients receiving enoxaparin, GP Ilb/Illa inhibitors and clopidogrel: Insight from ELECT.” In Circulation, 108:356–356. LIPPINCOTT WILLIAMS & WILKINS, 2003.
       Link to Item
    • Halkin, A., B. D. Rutherford, E. Garcia, M. Fahy, and J. E. Tcheng. “Predictors of left ventricular ejection fraction following primary percutaneous intervention for acute myocardial infarction.” In Circulation, 108:396–396. LIPPINCOTT WILLIAMS & WILKINS, 2003.
       Link to Item
    • Halkin, A., E. Aymong, E. Nikolsky, J. E. Tcheng, B. D. Rutherford, C. Costantini, C. L. Grines, and G. W. Stone. “Marked survival benefit of peri-procedural beta-blockers in patients with acute myocardial infarction undergoing primary angioplasty not previously treated with beta-blockers.” In Circulation, 108:467–467. LIPPINCOTT WILLIAMS & WILKINS, 2003.
       Link to Item
    • Harrison, J. K., J. B. Hermiller, G. W. Vetrovec, J. E. Smith, M. W. Pulsipher, M. J. Kern, E. H. Conn, et al. “A randomized study of 1276 patients undergoing PCI using iodixanol (Visipaque) vs iopamidol (Isovue); Comparison of in-hospital and 30 day major adverse cardiac events. The results of the VICC trial.” In Circulation, 108:354–55. LIPPINCOTT WILLIAMS & WILKINS, 2003.
       Link to Item
    • Prasad, A., G. Stone, E. Aymong, P. J. Zimetbaum, M. McLaughlin, R. Mehran, E. Garcia, et al. “Impact of ST-segment resolution following primary angioplasty on outcomes after myocardial infarction in the elderly: An analysis from the controlled abciximab and device investigation to lower late angioplasty complications (CADILLAC) trial.” In Circulation, 108:537–38. LIPPINCOTT WILLIAMS & WILKINS, 2003.
       Link to Item
    • Aymong, E., M. Fahy, A. Lansky, R. Mehran, C. L. Grines, D. A. Cox, C. E. Garcia, et al. “Can stents and glycoprotein IIb/IIIa inhibitors improve the prognosis of young patients with acute myocardial infarction? A report from the controlled abciximab and device investigation to lower late angioplasty complications (CADILLAC) study.” In American Journal of Cardiology, 92:142L-143L. EXCERPTA MEDICA INC, 2003.
       Link to Item
    • Costa, R. A., Y. Tsuchiya, M. Tarawali, H. Marginean, R. Sanchez, E. Cristea, R. Mehran, et al. “Impact of age on the outcomes of women with acute myocardial infarction undergoing primary coronary stenting.” In American Journal of Cardiology, 92:115L-116L. EXCERPTA MEDICA INC, 2003.
       Link to Item
    • Costantini, C. O., A. J. Lansky, R. A. Costa, R. Mehran, E. Aymong, D. A. Cox, J. E. Tcheng, et al. “Impact of myocardial blush analysis methodologies in predicting short and long-term mortality after primary angioplasty. The CADILLAC trial.” In American Journal of Cardiology, 92:43L-43L. EXCERPTA MEDICA INC, 2003.
       Link to Item
    • Costantini, C. O., H. Marginea, E. Cristea, Y. Tsyshiya, R. A. Costa, T. Stuckey, M. Turco, et al. “Are there any angiographic predictors of abciximab benefit after primary angioplasty for acute myocardial infarction? Analysis from the CADILLAC trial.” In American Journal of Cardiology, 92:41L-41L. EXCERPTA MEDICA INC, 2003.
       Link to Item
    • Halkin, A., E. Nikolsky, E. Aymong, R. Mehran, J. E. Tcheng, D. A. Cox, T. Stuckey, A. J. Lansky, and G. W. Stone. “The survival benefit of periprocedural beta-blockers in patients with acute myocardial infarction undergoing primary angioplasty is determined by use of these drugs before admission.” In American Journal of Cardiology, 92:228L-228L. EXCERPTA MEDICA INC, 2003.
       Link to Item
    • Harjai, K. J., C. L. Grines, G. W. Stone, A. J. Lansky, E. Aymong, M. Fahy, D. A. Cox, et al. “Does the use of heparin after primary angioplasty for acute myocardial infarction in patients not receiving glycoprotein IIb/IIIa antagonists alleviate recurrent cardiac ischemia? Insights from the CADILLAC study.” In American Journal of Cardiology, 92:42L-42L. EXCERPTA MEDICA INC, 2003.
       Link to Item
    • Kandzari, D. E., M. Labinaz, W. J. Cantor, D. S. Gallup, V. Hasselblad, D. Joseph, A. Allen, et al. “Reduction of ischemic injury following coronary intervention: Results of the MC-1 to eliminate necrosis and damage trial (MEND-1).” In American Journal of Cardiology, 92:128L-128L. EXCERPTA MEDICA INC, 2003.
       Link to Item
    • Nikolsky, E., E. Aymong, A. J. Lansky, G. W. Stone, M. Turco, D. A. Cox, J. E. Tcheng, et al. “Anemia worsens prognosis after primary Angioplasty in acute myocardial infarction: Analysis from the cadillac study.” In American Journal of Cardiology, 92:143L-143L. EXCERPTA MEDICA INC, 2003.
       Link to Item
    • Rebeiz, A. G., M. E. Campbell, J. G. Toffaletti, E. H. McDonnell, M. H. Sketch, and J. E. Tcheng. “Activated clotting time values measured with the actalyke machine are consistently lower than measurements obtained with the Hemochron-801.” In American Journal of Cardiology, 92:130L-131L. EXCERPTA MEDICA INC, 2003.
       Link to Item
    • Sadeghi, H. M., C. L. Grines, R. Mehran, A. J. Lansky, M. Fahy, D. A. Cox, J. E. Tcheng, et al. “Incidence and implications of in-hospital acquired thromhocytopenia in patients undergoing primary angioplasty for acute myocardial infarction.” In American Journal of Cardiology, 92:40L-40L. EXCERPTA MEDICA INC, 2003.
       Link to Item
    • Stuckey, T. D., C. L. Grines, D. A. Cox, B. R. Brodie, M. Turco, P. Zimetbaum, J. E. Tcheng, et al. “Does stenting and glycoprotein IIb/IIIa receptor blockade improve ST segment recovery and outcome in patients undergoing primary angioplasty in acute myocardial infarction? The CADILLAC trial.” In American Journal of Cardiology, 92:41L-42L. EXCERPTA MEDICA INC, 2003.
       Link to Item
    • Vagaonescu, T. D., C. L. Grines, D. A. Cox, E. Garcia, J. E. Tcheng, J. J. Griffin, G. Guagliumi, et al. “Does treatment with abciximab influence survival in patients with acute myocardial infarction and elevated baseline white blood cell count undergoing primary angioplasty? The CADILLAC trial.” In American Journal of Cardiology, 92:228L-228L. EXCERPTA MEDICA INC, 2003.
       Link to Item
    • Lowe, R., G. A. Lamas, D. E. Kandzari, J. E. Tcheng, G. Knatterud, G. B. J. Mancini, H. White, et al. “Does ventricular geometry simply measure ejection fraction? An analysis from the occluded artery trial (OAT).” In Heart, 89:A11–A11. B M J PUBLISHING GROUP, 2003.
       Link to Item
    • Ashby, D. T., J. E. Tcheng, C. L. Grines, D. A. Cox, R. Mehran, M. P. Fahy, E. Garcia, et al. “Outcomes in patients requiring bail-out abciximab during primary intervention in acute myocardial infarction: Analysis from the CADILLAC trial.” In Journal of the American College of Cardiology, 41:333A-334A. ELSEVIER SCIENCE INC, 2003.
       Link to Item
    • Aymong, E. D., C. L. Grines, D. A. Cox, E. Garcia, J. E. Tcheng, J. J. Griffin, G. Guagliumi, et al. “Predictors and sequelae of subacute thrombosis after percutaneous intervention in acute myocardial infarction: The CADILLAC trial.” In Journal of the American College of Cardiology, 41:393A-393A. ELSEVIER SCIENCE INC, 2003.
       Link to Item
    • Aymong, E. D., M. G. McLaughlin, P. Zimetbaum, C. L. Grines, J. E. Tcheng, D. A. Cox, T. D. Stuckey, et al. “Prognostic value of the absolute degree of ST-segment elevation of the ECG at baseline and after primary angioplasty: Analysis from the CADILLAC trial.” In Journal of the American College of Cardiology, 41:323A-323A. ELSEVIER SCIENCE INC, 2003.
       Link to Item
    • Brodie, B. R., B. Gersh, T. D. Stuckey, P. Zimetbaum, M. G. McLaughlin, E. D. Aymong, R. Mehran, et al. “Relationship between time to treatment, electrocardiographic ST-segment resolution, and outcomes with primary percutaneous coronary intervention for acute myocardial infarction: Results from the CADILLAC trial.” In Journal of the American College of Cardiology, 41:342A-343A. ELSEVIER SCIENCE INC, 2003.
       Link to Item
    • Brodie, B. R., D. A. Cox, T. D. Stuckey, M. Turco, E. Garcia, J. J. Griffin, M. Fahy, et al. “How important is time to treatment with primary percutaneous coronary intervention for acute myocardial infarction? Results from the CADILLAC trial.” In Journal of the American College of Cardiology, 41:368A-368A. ELSEVIER SCIENCE INC, 2003.
       Link to Item
    • Dery, J. P., G. A. Braden, A. M. Lincoff, D. J. Kereiakes, K. F. Browne, T. Little, B. S. George, et al. “Abciximab readministration: Final results of the Reopro(fi) read ministration registry.” In Journal of the American College of Cardiology, 41:77A-78A. ELSEVIER SCIENCE INC, 2003.
       Link to Item
    • Kandzari, D. E., J. E. Tcheng, C. L. Grines, D. J. Cohen, A. Bakhai, D. A. Cox, T. D. Stuckey, et al. “Safety of an early discharge strategy following primary intervention with adjunctive glycoprotein IIb/IIIa inhibition: The CADILLAC trial.” In Journal of the American College of Cardiology, 41:538A-539A. ELSEVIER SCIENCE INC, 2003.
       Link to Item
    • Kandzari, D. E., J. E. Tcheng, C. L. Grines, M. Effron, D. A. Cox, E. Garcia, J. J. Griffin, et al. “Benefits and risks of abciximab use in primary Angioplasty for acute myocardial infarction: The CADILLAC trial.” In Journal of the American College of Cardiology, 41:357A-357A. ELSEVIER SCIENCE INC, 2003.
       Link to Item
    • Kandzari, D. E., V. Hasselblad, J. E. Tcheng, G. W. Stone, R. M. Califf, S. J. Brener, G. Montalescot, F. J. Neumann, A. Kastrati, and R. A. Harrington. “Improved clinical outcomes with abciximab therapy in acute myocardial infarction: A systematic overview of randomized clinical trials.” In Journal of the American College of Cardiology, 41:333A-333A. ELSEVIER SCIENCE INC, 2003.
       Link to Item
    • McLaughlin, M. G., G. Gardner, E. D. Aymong, R. Mehran, A. J. Lansky, C. L. Grines, J. E. Tcheng, et al. “ST-segment elevation resolution as a predictor of mortality in patients with thrombolysis in myocardial infarction III flow in the infarct artery after primary angioplasty: The CADILLAC trial.” In Journal of the American College of Cardiology, 41:392A-392A. ELSEVIER SCIENCE INC, 2003.
       Link to Item
    • Sadeghi, H. M., C. L. Grines, R. Mehran, H. R. Chandra, M. Fahy, D. A. Cox, E. Garcia, et al. “Magnitude and impact of after hours treatment delay in patients undergoing primary Angioplasty for acute myocardial infarction: The CADILLAC trial.” In Journal of the American College of Cardiology, 41:1A-1A. ELSEVIER SCIENCE INC, 2003.
       Link to Item
    • Sadeghi, H. M., C. L. Grines, R. Mehran, S. R. Dixon, A. J. Lansky, M. Fahy, D. A. Cox, et al. “Marked mortality risk of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction.” In Journal of the American College of Cardiology, 41:384A-384A. ELSEVIER SCIENCE INC, 2003.
       Link to Item
    • Turco, M. A., D. A. Cox, E. Garcia, J. E. Tcheng, J. J. Griffin, G. Guagliumi, T. D. Stuckey, et al. “Baseline features and clinical results in patients excluded from randomization from a large international trial of reperfusion strategies in acute myocardial infarction: The CADILLAC registry.” In Journal of the American College of Cardiology, 41:368A-368A. ELSEVIER SCIENCE INC, 2003.
       Link to Item
    • Turco, M. A., M. Fahy, R. A. Mehran, A. Lansky, C. L. Grines, J. E. Tcheng, E. Garcia, et al. “Predictors of treatment delay in patients with acute myocardial infarction undergoing primary angioplasty: An analysis from the CADILLAC trial.” In Journal of the American College of Cardiology, 41:376A-376A. ELSEVIER SCIENCE INC, 2003.
       Link to Item
    • DENARDO, S. “P2870 Elective percutaneous coronary intervention using anti-platelet therapy alone, without unfractionated heparin or other anti-thrombin therapy.” In European Heart Journal, 24:548–548. Elsevier BV, 2003. https://doi.org/10.1016/s0195-668x(03)95648-x.
       Full Text
    • KONG, D. “P2856 Cumulative meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions.” In European Heart Journal, 24:544–544. Elsevier BV, 2003. https://doi.org/10.1016/s0195-668x(03)95634-x.
       Full Text
    • Bakhai, A., G. W. Stone, S. A. Murphy, L. Githiora, R. H. Berezin, S. Gedney, P. Hormel, et al. “Cost-effectiveness of coronary stenting and abciximab for patients with AMI: Results from the CADILLAC trial.” In Circulation, 106:518–518. LIPPINCOTT WILLIAMS & WILKINS, 2002.
       Link to Item
    • Denardo, S. J., K. E. Davis, and J. E. Tcheng. “Adjunctive pharmacotherapy confined to an anti-platelet regimen during elective percutaneous coronary intervention.” In Circulation, 106:517–517. LIPPINCOTT WILLIAMS & WILKINS, 2002.
       Link to Item
    • Lansky, A. J., C. Costantini, K. Desai, M. Adamian, D. Cox, J. E. Tcheng, J. Griffin, et al. “Exposing the gender gap in outcomes after primary intervention for acute myocardial infarction: Results from the CADILLAC trial.” In Circulation, 106:491–92. LIPPINCOTT WILLIAMS & WILKINS, 2002.
       Link to Item
    • Weisz, G., D. Ashby, E. Garcia, J. E. Tcheng, J. J. Griffin, G. Guagliumi, T. F. Stuckey, et al. “Impact of smoking status in patients with acute myocardial infarction treated with primary percutaneous intervention: The smoker's paradox revisited.” In Circulation, 106:697–697. LIPPINCOTT WILLIAMS & WILKINS, 2002.
       Link to Item
• Teaching & Mentoring
• 

  Recent Courses

  • CLP 212: Informatics for Clinicians 2022
  • CLP 212: Informatics for Clinicians 2021
  • CLP 212: Informatics for Clinicians 2020
• Scholarly, Clinical, & Service Activities
• 

  Service to the Profession

  • Chair. Informatics and Health IT Committee. American College of Cardiology. 1996  1996

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.